CA2394900C - Diabetes management system - Google Patents
Diabetes management system Download PDFInfo
- Publication number
- CA2394900C CA2394900C CA002394900A CA2394900A CA2394900C CA 2394900 C CA2394900 C CA 2394900C CA 002394900 A CA002394900 A CA 002394900A CA 2394900 A CA2394900 A CA 2394900A CA 2394900 C CA2394900 C CA 2394900C
- Authority
- CA
- Canada
- Prior art keywords
- insulin
- glucose
- subject
- unit
- meal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
Abstract
A system is provided that enables glycemic control for a subject. The system includes an insulin delivery unit, a glucose sensor, and a control unit. The control unit includes a processor unit that receives glucose value readings from the glucose sensor, executes an algorithm that predicts a glucose value at a pre-determined time in the future, compares that predicted glucose value to a pre-determined glucose value range, and determines a corrective amount of insulin to be administered when the predictive glucose value lies outside of the pre-determined glucose value range. The control unit also includes a communication unit that transmits the corrective amount to the delivery unit.
Description
DIABETES MANAGEMENT SYSTEM
FIELD OF THE INVENTION
The present invention relates to a system for managing diabetes. More particularly, the present invention relates to an automated system for determining the timing and amount of insulin administration to a subject in the treatment of diabetes.
BACKGROUND AND SUMMARY OF THE INVENTION
Typically, insulin therapy is based upon a set of rules that employ periodic glucose measurements to make insulin recommendations to manage glucose levels.
The rules are based on estimates of an individual subject's response to carbohydrates, insulin and exercise. In practice, these rules are used to present an initial therapy.
The subject then individualizes this therapy with the help of a health-care provider by analyzing the glycemic results achieved to date. This data is in the form of a written or electronic logbook that the subject maintains regarding exercise, food consumption, insulin doses and glucose measurements. The rules are applied for administering insulin and/or carbohydrates based on experience and abnormal glucose values.
Rules are generally updated when the therapy results in degraded blood glucose control.
Electronic diabetes management systems have been developed to assist subjects in the implementation of insulin administration regimens. See, for example U.S. Pat. Nos. 5,019,974; 4,731,726; 5,822,715; 5,840,020. See also, EP 1 102 A2.
According to the present invention, a system far providing glycemic control to a subject is provided. The system comprises an insulin delivery unit, a glucose sensor, and a control unit. The control unit includes a processor unit that receives glucose value readings from the glucose sensor, executes an algorithm that predicts a glucose value at a pre-determined time in the future, compares that predicted glucose value to a pre-determined glucose value range, and determines a corrective amount of insulin to be administered when the predictive glucose value lies outside of the pre-determined glucose value range. The control unit also includes a communication unit that transmits the corrective amount to the delivery unit. In at least one embodiment, a predictive model is provided that is based on the following equation: DG = -(TotalInsuRemain - BasalReq) * Sensitivity, wherein DG = future change in glucose level at a pre-determined time, TotalInsuRemain = amount of insulin r emaining in the subject's system at the current time, BasalReq = how much insulin the subject is estimated to need at the pre-determined time, and Sensitivity = Insulin sensitivity.
In addition, a system for providing glycemic control to a subject is provided in accordance with the present invention. The system comprises a sensor formed to conduct a glucose measurement of a subject, a control unit that includes a processor unit that is formed to accept data from the subject on insulin sensitivity and basal rate, to execute an algorithm that generates a predictive value of the subject's glucose level at a predetermined time in the future based upon the glucose measurement from the sensor and the data, and to compute a corrective action when the predictive value lies outside of a predetermined target range. The system also includes an insulin delivery unit in communication with the control unit. The delivery unit is formed to administer automatically a dosage of insulin to the subject based upon the computed corrective action of the control unit.
Still further in accordance with the present invention a method for providing glycemic control to a subject is provided. The method comprises the steps of determining the glucose value of a subject and inputting the glucose value into at least one processor. The at least one processor is formed to execute at least one algorithm that anticipates the future effects of insulin that has been previously delivered to the subject, to incorporate constraints on insulin delivery and glucose deviations, and to determine a corrective amount of insulin to be administered when the predictive glucose value lies outside of the pre-determined glucose value range. Next, the desired insulin dosage is delivered automatically to the subject and both the determining and inputting steps are repeated.
In addition, a system for providing glycemic control to a subject is provided.
The system comprises means for delivering insulin to a subject, means for determining a glucose value from the subject, and a control unit including a processor unit that is formed to compare the glucose value to a pre-determined glucose value range. The processor unit is also formed to determine a corrective amount of insulin to be administered when the predictive glucose value lies outside of the pre-determined glucose value range and to transmit the corrective amount to the delivering means.
According to another embodiment of the present invention a system for predicting a future glucose value of a subject at a predetermined time is provided.
The system comprises a control unit that includes a processor unit formed to predict the future glucose value with an algorithm DG = -(TotalInsuRemain - BasalReq) Sensitivity, wherein DG = future change in glucose levels at a pre-determined time, TotalInsuRemain = amount of insulin remaining in the subject's system at a current time, and BasalReq = how much insulin the subject is estimated to need to maintain the current glucose level, and Sensitivity = Insulin sensitivity.
According to still another embodiment of the present invention a system for recommending an insulin dose that compensates for meals for a subject is provided.
The system comprises a control unit that includes a processor unit formed to compensate for meals with a feedforward algorithm Dose = carbohydrates *
insulin-to-carb-ratio * amp rn,e - intercept, wherein Dose = Insulin dose, carbohydrates =
grams of carbohydrates, insulin-to-carb-ratio = Insulin to Carbohydrate Ratio, ameai type = meal dependent scaling factor, and intercept = intercept to allow a linear fit for sizes of the meals.
Additional features of the invention will become apparent to those skilled in the art upon consideration of the following detailed description of the preferred embodiment exemplifying the best mode of carrying out the invention BRIEF DESCRIPTION OF THE DRAWINGS
The detailed description particularly refers to the accompanying figures in which:
Fig. 1 is a schematic of the system of the present invention.
Fig. 2 is a graph showing an example of a glucose trace during a 24 hour control day with limited activity and three meals.
Fig. 3 is a graph showing the glucose concentration for 22 subjects over a single day where the amount of insulin dosed for each meal was computed from the subjects' insulin-to-carbohydrate ratio.
Fig. 4 is a graph showing the glucose concentration for 12 subjects over a single day (total of 30 experiments) where the amount of insulin dosed for each meal was computed through the algorithm from the manual entry of the number of grams of carbohydrates (for meals with 60% of their calories coming from carbohydrates).
Fig. 5 is a schematic of the system utilizing the feedforward algorithm.
Fig. 6 is a graph showing an assumed shape of the insulin effect on a subject for purposes of an empirical algorithm.
FIELD OF THE INVENTION
The present invention relates to a system for managing diabetes. More particularly, the present invention relates to an automated system for determining the timing and amount of insulin administration to a subject in the treatment of diabetes.
BACKGROUND AND SUMMARY OF THE INVENTION
Typically, insulin therapy is based upon a set of rules that employ periodic glucose measurements to make insulin recommendations to manage glucose levels.
The rules are based on estimates of an individual subject's response to carbohydrates, insulin and exercise. In practice, these rules are used to present an initial therapy.
The subject then individualizes this therapy with the help of a health-care provider by analyzing the glycemic results achieved to date. This data is in the form of a written or electronic logbook that the subject maintains regarding exercise, food consumption, insulin doses and glucose measurements. The rules are applied for administering insulin and/or carbohydrates based on experience and abnormal glucose values.
Rules are generally updated when the therapy results in degraded blood glucose control.
Electronic diabetes management systems have been developed to assist subjects in the implementation of insulin administration regimens. See, for example U.S. Pat. Nos. 5,019,974; 4,731,726; 5,822,715; 5,840,020. See also, EP 1 102 A2.
According to the present invention, a system far providing glycemic control to a subject is provided. The system comprises an insulin delivery unit, a glucose sensor, and a control unit. The control unit includes a processor unit that receives glucose value readings from the glucose sensor, executes an algorithm that predicts a glucose value at a pre-determined time in the future, compares that predicted glucose value to a pre-determined glucose value range, and determines a corrective amount of insulin to be administered when the predictive glucose value lies outside of the pre-determined glucose value range. The control unit also includes a communication unit that transmits the corrective amount to the delivery unit. In at least one embodiment, a predictive model is provided that is based on the following equation: DG = -(TotalInsuRemain - BasalReq) * Sensitivity, wherein DG = future change in glucose level at a pre-determined time, TotalInsuRemain = amount of insulin r emaining in the subject's system at the current time, BasalReq = how much insulin the subject is estimated to need at the pre-determined time, and Sensitivity = Insulin sensitivity.
In addition, a system for providing glycemic control to a subject is provided in accordance with the present invention. The system comprises a sensor formed to conduct a glucose measurement of a subject, a control unit that includes a processor unit that is formed to accept data from the subject on insulin sensitivity and basal rate, to execute an algorithm that generates a predictive value of the subject's glucose level at a predetermined time in the future based upon the glucose measurement from the sensor and the data, and to compute a corrective action when the predictive value lies outside of a predetermined target range. The system also includes an insulin delivery unit in communication with the control unit. The delivery unit is formed to administer automatically a dosage of insulin to the subject based upon the computed corrective action of the control unit.
Still further in accordance with the present invention a method for providing glycemic control to a subject is provided. The method comprises the steps of determining the glucose value of a subject and inputting the glucose value into at least one processor. The at least one processor is formed to execute at least one algorithm that anticipates the future effects of insulin that has been previously delivered to the subject, to incorporate constraints on insulin delivery and glucose deviations, and to determine a corrective amount of insulin to be administered when the predictive glucose value lies outside of the pre-determined glucose value range. Next, the desired insulin dosage is delivered automatically to the subject and both the determining and inputting steps are repeated.
In addition, a system for providing glycemic control to a subject is provided.
The system comprises means for delivering insulin to a subject, means for determining a glucose value from the subject, and a control unit including a processor unit that is formed to compare the glucose value to a pre-determined glucose value range. The processor unit is also formed to determine a corrective amount of insulin to be administered when the predictive glucose value lies outside of the pre-determined glucose value range and to transmit the corrective amount to the delivering means.
According to another embodiment of the present invention a system for predicting a future glucose value of a subject at a predetermined time is provided.
The system comprises a control unit that includes a processor unit formed to predict the future glucose value with an algorithm DG = -(TotalInsuRemain - BasalReq) Sensitivity, wherein DG = future change in glucose levels at a pre-determined time, TotalInsuRemain = amount of insulin remaining in the subject's system at a current time, and BasalReq = how much insulin the subject is estimated to need to maintain the current glucose level, and Sensitivity = Insulin sensitivity.
According to still another embodiment of the present invention a system for recommending an insulin dose that compensates for meals for a subject is provided.
The system comprises a control unit that includes a processor unit formed to compensate for meals with a feedforward algorithm Dose = carbohydrates *
insulin-to-carb-ratio * amp rn,e - intercept, wherein Dose = Insulin dose, carbohydrates =
grams of carbohydrates, insulin-to-carb-ratio = Insulin to Carbohydrate Ratio, ameai type = meal dependent scaling factor, and intercept = intercept to allow a linear fit for sizes of the meals.
Additional features of the invention will become apparent to those skilled in the art upon consideration of the following detailed description of the preferred embodiment exemplifying the best mode of carrying out the invention BRIEF DESCRIPTION OF THE DRAWINGS
The detailed description particularly refers to the accompanying figures in which:
Fig. 1 is a schematic of the system of the present invention.
Fig. 2 is a graph showing an example of a glucose trace during a 24 hour control day with limited activity and three meals.
Fig. 3 is a graph showing the glucose concentration for 22 subjects over a single day where the amount of insulin dosed for each meal was computed from the subjects' insulin-to-carbohydrate ratio.
Fig. 4 is a graph showing the glucose concentration for 12 subjects over a single day (total of 30 experiments) where the amount of insulin dosed for each meal was computed through the algorithm from the manual entry of the number of grams of carbohydrates (for meals with 60% of their calories coming from carbohydrates).
Fig. 5 is a schematic of the system utilizing the feedforward algorithm.
Fig. 6 is a graph showing an assumed shape of the insulin effect on a subject for purposes of an empirical algorithm.
Fig. 7 is a schematic of a portion of the system of Fig. 5.
Fig. 8 is a schematic of a portion of the system of Fig. 5.
DETAILED DESCRIPTION OF THE DRAWINGS
A subject with diabetes is confronted with ongoing therapeutic decisions to manage their disease effectively. This management requires an understanding of the subject's response to meals, exercise, insulin, stress, alcohol, medication, hormones, illness, and a number of other factors that interact in complex ways.
Management requires complex calculations, glucose measurements, and insulin injections.
In an effort to manage the disease, individuals may elect to make a transition from multiple daily spot glucose measurements to continuous glucose monitoring.
The system of the present invention incorporates algorithms with continuous feedback for glycemic control that enables management with continuous monitoring. One embodiment of the present involves subcutaneous glucose monitoring and subcutaneous delivery of rapid-acting insulin (e.g. HUMALOG~, Eli Lilly and Company, Indianapolis, IN or NOVORAPID~, Novo Nordisk A/S, Bagsvaerd, Denmark). In addition to time-dependent variations of physiological conditions, the control algorithm compensates for delays on the measurement side (physical or technology-related lags and physiological lags between subcutaneous space and blood) as well as on the delivery side (delayed insulin action due to peripheral delivery). In order to achieve acceptable glycemic control, especially under disturbance challenges of meals and physical activity, feedback-based insulin dose adjustment is used in a feedback algorithm. Further, a feedforward algorithm is notified of pending meals in advance and this notification generally includes information about size (carbohydrate amount) and type of the meal (relative speed of the meal) to be ingested.
Thus, the system of the present invention permits the individual to manage their diabetes with minimal intervention with near normal glycemic control.
This system uses qualitative and quantitative information regarding interstitial glucose values and administered insulin to determine the timing and amount of insulin administration, and preferably carbohydrate intake recommendations. Additional information, such as meals, exercise, stress, illness, and alcohol consumption may also be utilized by the system in accordance with this disclosure. In preferred 't embodiments, the system of the present invention analyzes past data to make modifications to the existing therapy.
This system 14 in accordance with the present invention comprises an insulin delivery unit 12, a glucose sensor 16, and a control unit 14. See Fig. 1. The concentration of interstitial glucose in a diabetic changes due to external influences, non-limiting examples of which include insulin administration, meals and exercise.
Sensor 16 measures the glucose and reports the value to control unit 14.
Control unit 14 responds to the measured glucose levels by determining the appropriate amount of insulin to administer in order to normalize glucose levels within a pre-determined target range. This target range for glucose is from about 60 mg/dl to about 250 mg/dl, preferably about 80 mg/dl to about 210 mg/dl, and most preferably about 90 mg/dl to about 150 mg/dl. It is appreciated, however, that the target range may exceed the range of about 60 mg/dl to about 250 mg/dl in accordance with this disclosure based upon the individualized needs of the subject. Control unit I4 then directs delivery unit 12 to administer the appropriate amount of insulin to the subject.
In at least one embodiment, control unit 14 also stores feedback and feedforward algorithms, the glucose concentrations, and the amount of insulin administered as well as the times of administration in a memory unit. It is further appreciated that the memory unit may also store the carbohydrates consumed and the times they were consumed as well as the duration and intensity of any exercise performed by the subject. This memory is formed with memory components, a non-limiting example of which is known as RAM, which is well known in the prior art.
The system of the present invention operates upon an assumption that there exists an insulin basal rate for a subject that is required to maintain a steady-state glucose level (G) at a specified therapy level. It is understood that this basal rate can be either a fixed value or vary with time. Based upon this basal rate, it is possible to select an insulin infusion rate to meet the target range of the desirable glucose level.
The system of the present invention utilizes this pre-determined basal rate in making its insulin dosage recommendations in order to hold the glucose level within the target range. It is appreciated that this basal rate is individualized and can be determined using a variety of well known methods.
Insulin delivery unit 12 is formed to administer automatically a dosage of insulin to the subject based upon the computed corrective action of the control unit 14. Operation of delivery uut 12 depends upon subj ect-specific recommendations from control unit 14 and occurs at a pre-determined time interval or cycle. It is appreciated that unit 12 can deliver a variety of insulin doses in accordance with this disclosure. Insulin dosages generally range from 0 U to about 15U per cycle, which are based upon the projected insulin needs of the subject. It is appreciated that while these time intervals or cycles can vary, non-limiting examples of appropriate time intervals range from about 1 minute to about 1 hour, preferably 5 minutes to about 30 minutes, most preferably about 10 minutes. Delivery unit 12 can be a continuous type system(e.g. an "insulin pump) a semi continuous system, or a discrete delivery system. In addition, delivery unit 12 can be any one of a variety of commercially available delivery units in accordance with this disclosure. A non-limiting example of a suitable semi-continuous delivery unit is a H-Tron Insulin pump, commercially available from Disetronic Medical Systems, Inc., St. Paul, MN. Non-limiting examples of suitable discrete delivery units include B-D~ PEN Insulin Delivery Device, commercially available from BD, Franklin Lakes, NJ and the Lilly Pen, commercially available from Eli Lilly and Company, Indianapolis, IN.
Glucose sensor 16 draws a body fluid sample from a subject for testing.
Operation of sensor 16 occurs at a pre-determined time interval or cycle. This time interval preferably corresponds with the time intervals of the operation of delivery unit 12. In use, sensor 16 draws samples from the subject about every 1 minute to about 1 hour, more preferably about every 5 minutes to about 20 minutes, most preferably about every 10 minutes. Sensor 16 can be a continuous glucose-sensing unit, a semi-continuous glucose-sensing unit, or a discrete glucose-sensing unit.
Further, suitable glucose sensors may be electrochemical, microdialysis, transdermal, or noninvasive.
For example, electrochemical glucose sensors are known in which glucose concentration can be measured in a capillary blood sample collected by the subject from the fingertip and then applied to a test element, for instance. A device based on sampling blood is described in U.S. Patent Nos. 5,288,636; 5,053,199;
5,366,609; and 4,891,319. To determine glucose values, it is also possible to implant electrochemical measurement sensors in the body (e.g., intravasal, interstitial). See, for example the MiniMed Continuous Glucose Monitoring System -CGMS-, commercially available from MiniMed Inc. Northridge, CA.
Fig. 8 is a schematic of a portion of the system of Fig. 5.
DETAILED DESCRIPTION OF THE DRAWINGS
A subject with diabetes is confronted with ongoing therapeutic decisions to manage their disease effectively. This management requires an understanding of the subject's response to meals, exercise, insulin, stress, alcohol, medication, hormones, illness, and a number of other factors that interact in complex ways.
Management requires complex calculations, glucose measurements, and insulin injections.
In an effort to manage the disease, individuals may elect to make a transition from multiple daily spot glucose measurements to continuous glucose monitoring.
The system of the present invention incorporates algorithms with continuous feedback for glycemic control that enables management with continuous monitoring. One embodiment of the present involves subcutaneous glucose monitoring and subcutaneous delivery of rapid-acting insulin (e.g. HUMALOG~, Eli Lilly and Company, Indianapolis, IN or NOVORAPID~, Novo Nordisk A/S, Bagsvaerd, Denmark). In addition to time-dependent variations of physiological conditions, the control algorithm compensates for delays on the measurement side (physical or technology-related lags and physiological lags between subcutaneous space and blood) as well as on the delivery side (delayed insulin action due to peripheral delivery). In order to achieve acceptable glycemic control, especially under disturbance challenges of meals and physical activity, feedback-based insulin dose adjustment is used in a feedback algorithm. Further, a feedforward algorithm is notified of pending meals in advance and this notification generally includes information about size (carbohydrate amount) and type of the meal (relative speed of the meal) to be ingested.
Thus, the system of the present invention permits the individual to manage their diabetes with minimal intervention with near normal glycemic control.
This system uses qualitative and quantitative information regarding interstitial glucose values and administered insulin to determine the timing and amount of insulin administration, and preferably carbohydrate intake recommendations. Additional information, such as meals, exercise, stress, illness, and alcohol consumption may also be utilized by the system in accordance with this disclosure. In preferred 't embodiments, the system of the present invention analyzes past data to make modifications to the existing therapy.
This system 14 in accordance with the present invention comprises an insulin delivery unit 12, a glucose sensor 16, and a control unit 14. See Fig. 1. The concentration of interstitial glucose in a diabetic changes due to external influences, non-limiting examples of which include insulin administration, meals and exercise.
Sensor 16 measures the glucose and reports the value to control unit 14.
Control unit 14 responds to the measured glucose levels by determining the appropriate amount of insulin to administer in order to normalize glucose levels within a pre-determined target range. This target range for glucose is from about 60 mg/dl to about 250 mg/dl, preferably about 80 mg/dl to about 210 mg/dl, and most preferably about 90 mg/dl to about 150 mg/dl. It is appreciated, however, that the target range may exceed the range of about 60 mg/dl to about 250 mg/dl in accordance with this disclosure based upon the individualized needs of the subject. Control unit I4 then directs delivery unit 12 to administer the appropriate amount of insulin to the subject.
In at least one embodiment, control unit 14 also stores feedback and feedforward algorithms, the glucose concentrations, and the amount of insulin administered as well as the times of administration in a memory unit. It is further appreciated that the memory unit may also store the carbohydrates consumed and the times they were consumed as well as the duration and intensity of any exercise performed by the subject. This memory is formed with memory components, a non-limiting example of which is known as RAM, which is well known in the prior art.
The system of the present invention operates upon an assumption that there exists an insulin basal rate for a subject that is required to maintain a steady-state glucose level (G) at a specified therapy level. It is understood that this basal rate can be either a fixed value or vary with time. Based upon this basal rate, it is possible to select an insulin infusion rate to meet the target range of the desirable glucose level.
The system of the present invention utilizes this pre-determined basal rate in making its insulin dosage recommendations in order to hold the glucose level within the target range. It is appreciated that this basal rate is individualized and can be determined using a variety of well known methods.
Insulin delivery unit 12 is formed to administer automatically a dosage of insulin to the subject based upon the computed corrective action of the control unit 14. Operation of delivery uut 12 depends upon subj ect-specific recommendations from control unit 14 and occurs at a pre-determined time interval or cycle. It is appreciated that unit 12 can deliver a variety of insulin doses in accordance with this disclosure. Insulin dosages generally range from 0 U to about 15U per cycle, which are based upon the projected insulin needs of the subject. It is appreciated that while these time intervals or cycles can vary, non-limiting examples of appropriate time intervals range from about 1 minute to about 1 hour, preferably 5 minutes to about 30 minutes, most preferably about 10 minutes. Delivery unit 12 can be a continuous type system(e.g. an "insulin pump) a semi continuous system, or a discrete delivery system. In addition, delivery unit 12 can be any one of a variety of commercially available delivery units in accordance with this disclosure. A non-limiting example of a suitable semi-continuous delivery unit is a H-Tron Insulin pump, commercially available from Disetronic Medical Systems, Inc., St. Paul, MN. Non-limiting examples of suitable discrete delivery units include B-D~ PEN Insulin Delivery Device, commercially available from BD, Franklin Lakes, NJ and the Lilly Pen, commercially available from Eli Lilly and Company, Indianapolis, IN.
Glucose sensor 16 draws a body fluid sample from a subject for testing.
Operation of sensor 16 occurs at a pre-determined time interval or cycle. This time interval preferably corresponds with the time intervals of the operation of delivery unit 12. In use, sensor 16 draws samples from the subject about every 1 minute to about 1 hour, more preferably about every 5 minutes to about 20 minutes, most preferably about every 10 minutes. Sensor 16 can be a continuous glucose-sensing unit, a semi-continuous glucose-sensing unit, or a discrete glucose-sensing unit.
Further, suitable glucose sensors may be electrochemical, microdialysis, transdermal, or noninvasive.
For example, electrochemical glucose sensors are known in which glucose concentration can be measured in a capillary blood sample collected by the subject from the fingertip and then applied to a test element, for instance. A device based on sampling blood is described in U.S. Patent Nos. 5,288,636; 5,053,199;
5,366,609; and 4,891,319. To determine glucose values, it is also possible to implant electrochemical measurement sensors in the body (e.g., intravasal, interstitial). See, for example the MiniMed Continuous Glucose Monitoring System -CGMS-, commercially available from MiniMed Inc. Northridge, CA.
Another possibility for the determination of glucose values is based on measurements in interstitial fluid. Devices are known with which small quantities of interstitial fluid can be collected through thin cannula and then analyzed. To perform subcutaneous measurements it is also possible to implant miniaturized catheters with which microdialysis or ultrafiltration can be performed, so that measured results can be provided at close intervals. A device based on microdialysis is described in U.S.
Patent No. 5,174,291. A device based on ultrafiltration is described in U.S.
Patent No. 4,777,953. An example of an implantable sensor is disclosed in U.S. Patent No.
6,049,727.
Further, non-invasive sensors are suitable in accordance with this disclosure.
Non-limiting examples of such known sensors include GLUCOWATCH~' Biographer, commercially available from Cygnus, Inc., Redwood City, CA., as well as sensors disclosed in U.S. Patent Nos. 5,730,714, 5,222,496, and 6,061,582.
It is appreciated that sensor 16 can be any one of a variety of i~x vivo or in vitro sensors in accordance with this disclosure. Since samples are drawn from a subject frequently, it is preferred that sensor 16 be implanted in the subject, such as the CGMS as described above.
Sensor 16 does not generally produce a glucose reading instantaneously, but rather, a period of time elapses between the time that a sample is extracted from the subject and the time that the glucose measurement is available from use by unit 14.
This time delay can range from about 1 minute to about 45 minutes, more typically from about 5 minutes to about 30 minutes, and most typically, the time delay for the glucose measurement is about 5 to about 15 minutes. System of the present invention recognizes that this time delay exists and control unit 14 is formed to compensate, or make corrections for the delay. It is also appreciated that a sensor may be used in the system of the present invention, which reduces or even eliminates this time delay.
Control unit 14, is formed to predict the current glucose value of the subject based upon the delayed glucose reading, the history of insulin infusions, the basal requirement, and the insulin sensitivity of the subject. Insulin sensitivity is defined herein as the expected drop of glucose concentration when lU of insulin is administered to the subject. It is understood that insulin sensitivity is individual to the subject and is determined over a period of time.
Unit 14 includes a processor unit that executes an algorithm to determine an insulin dosage recommendation and a communication unit that forwards that recommendation of the processor unit to the delivery unit 12. It is appreciated that non-limiting examples of suitable processor units include microprocessors, portable laptop computers, or mainframe computers. The communication unit or units can be of the type of a serial port, a RF port, an IR port, an ultrasound mode, or any number of commercially available communication units. Non-limiting examples of power sources suitable to power the processing and communication units can be solar power, battery power (throw away or rechargeable), conventional AC power, or mechanical power in accordance with this disclosure. It is appreciated that processor unit and communication unit can be assembled in one single device, or they can be discrete devices that communicate with each other through wired or wireless means (IR
link or RF link).
The processor unit of control unit 14 is a microprocessor. It is appreciated that the microprocessor may be any number of commercially available microprocessors.
A non-limiting example of a suitable microprocessor includes a personal digital assistant (PDA) that includes a display. The display enables the subject to input data and review data from unit 14. Non-limiting examples of data displayed by unit includes the glucose values, insulin doses and their times of administration, the carbohydrates consumed or to be consumed and the times they are consumed, and exercise performed or to be performed, the duration of the exercise, and the intensity of the exercise. In addition, non-limiting examples of the display include a data input unit with a visual display unit and/or an auditory/vibratory feedback unit in accordance with this disclosure. It is appreciated that data can also be inputted via a keyboard.
In addition, to processor unit and communication unit, the control unit 14 of the present invention preferably includes a memory unit. The memory unit stores the algorithms, the glucose concentrations, the amount of insulin administered, the times of administration, the carbohydrates consumed, the times the carbohydrates were consumed, and the duration and intensity of any exercise performed by the subject.
The memory unit is formed with memory components, non-limiting examples of which include a RAM unit, a disk drive unit, a hard disk drive unit, a tape drive unit, . CA 02394900 2002-07-24 or other data storage means, which are well known in the art. It is appreciated that the memory unit may be a discrete component rather than integral with the processor and communication units.
The memory unit can communicate with the processor and communication units through wired or wireless means (IR link or RF link). The processor unit of the control unit 14 predicts an expected drop in glucose over time after accounting for the time delay in the sensor using a feedback algorithm that is stored in the memory unit.
Based upon that drop, the processor unit makes a recommendation for the administration of additional insulin to the subject to reach a pre-determined target glucose level at a pre-determined time in the future. In preferred embodiments, as will be discussed hereafter; the processor unit also uses a feedforward algorithm stored in the memory unit that allows adjustment due to variations in a subject's glucose-insulin dynamics as well as meal related information. See Figs. 5, 7, and 8.
In at least one embodiment of the present invention, the control unit 14 operates using both levels of algorithms. The first level is a basal rate control or a feedback algorithm stored in the memory unit. The second level is a compensation control for meals and/or exercise or a feedforward algorithm that is also stored in the memory unit. See Figs. 5, 7 and 8. It is appreciated that the feedback algorithm operates on the assumption that there exists an insulin basal rate for a subject that is required to maintain a steady-state glucose level at a specified therapy level. This pre-determined basal rate is used by the feedback algorithm in making its insulin dosage recommendations. The feedback algorithm excludes insulin equivalents for meals and exercise from the prediction of a future glucose value.
Recommendations for doses of insulin to cover meals are made based upon the subject's experience (carbohydrate/insulin ratio or fixed dose) and lie outside of the feedback algorithms used by the control unit 14.
In the feedforward algorithm, the administered insulin dose is expected to ideally flatten or counteract the carbohydrates taken in the meal (or at least stay within a predetermined range of glucose values over a period of time). The feedforward algorithm reprocesses historical data of the subject to make a determination of an appropriate insulin dosage for categorized meals. Likewise, the insulin dose reduction due to exercise is based on historical data to determine the appropriate insulin dose reduction for categorized exercise. It is appreciated, that the feedback algorithm used by the processor unit of the control unit 14 does not see the effects of these feedforward meal-related insulin doses or exercise-related insulin reductions.
The control unit 14 uses the feedback algorithm in a predictive model to predict the future glucose level of a subject at a pre-determined time. The feedback algorithm is illustrated by equations (1-3). First, equation (1) is used to predict a current glucose value (for an expected delay in glucose measurement) as follows:
(1) InaulinDunriinn G(i + 1) = G(i) +' InsuTrac i InsuGluDro i + Basal Re uirement i Sensitivi ~ ) * P( )) q ( )~
i=i Wherein G (i) = glucose concentration i cycles in the past i = cycle InsuTrace (i) - series of pulses of insulin that were administered in the past (excluding meal-related insulin doses and exercise-related insulin reductions) normalized InsuGluDrop (i) = amount that the glucose is expected to drop on the next cycle due to insulin delivered at times in the past OT = time interval between cycles (in minutes) Basal Requirement (i) = amount of insulin required in the i'th cycle to maintain current glucose in the absence of disturbances Sensitivity = expected magnitude of glucose drop for lU of insulin.
Next, control unit 14 predicts a future change in glucose level in accordance with equation (2):
(2) aG = -(TotalInsuRemain - BasalReq) * Sensitivity Wherein 0G = expected future change in glucose levels TotalInsuRemain = expected amount of insulin remaining in the subject's system (excluding meal-related doses and exercise dose reductions) BasalReq = how much insulin the subject is estimated to need S Control unit 14 then makes a recommended insulin dose to reach the target range of glucose level in full time of the insulin action using equation (3):
(3) InsuRecommend = [G (0) + OG - Target] / Sensitivity + BasalNeed PerCycle Wherein InsuRecommend = recommended insulin dosage G (0) = predicted current glucose level Target = glucose target level BasalNeedPerCycle = basal requirements of the subject during each cycle The recommended dosage is rounded to the nearest 0.05 U to 0.1 U resolution.
Tt is appreciated that the recommended dosage need not be rounded or may be rounded to a different level of precision in accordance with the disclosure.
The recommendation of the control unit 14 resulting from the feedback algorithm is transmitted to the delivery unit 12. The transmission can take place over a fixed wire or preferably via telemetric connection (IR link or RF link). It is appreciated that the transmission can take place using any number of wired or wireless means in accordance with this disclosure. It is also possible that the subject may operate the delivery unit 12 themselves, such as an insulin pump outfitted with a transmission unit that transmits the administered insulin dose along with the time of administration to the control unit 14.
The feedforward algorithm is part of an insulin adaptation model used by unit 14 that allows the system to analyze past data and to make modifications to the existing therapy based upon that data. This adaptation model performs the function of an event handler 20, a meal compensator 22, a basal controller 24, and a dose nullifier 26. See Fig. 5. In practice, the adaptation model again assumes a basal insulin requirement and an insulin sensitivity, which is specific to the subject. It is appreciated that the subject initially inputs information on meals and exercise into control unit 14 based upon personal history. See Fig. 5, which is a schematic illustration of the feedforward algorithm of the adaptation model. The adaptation model uses this subject-provided data as well as the historical data gathered by the unit 14 to correct or refine the subject-provided data to make a recommended therapy as to the distribution and amount of insulin for meal related doses as well as exercise.
Thus, the adaptation model uses historical data for post processing to develop updated settings and functions for the particular subject. Specifically, the historical data is reprocessed by first mathematically removing all insulin from the dataset except for the particular subject's basal requirement of insulin. When the correct basal insulin rates) are applied, it is expected that the subject's glucose levels will remain nearly flat while fasting and for short pre-prandial periods. During meals, the glucose levels progressively increase with time and only during exercise is a decrease anticipated. Second, the distribution and amount of insulin doses are determined that provide a flat or sculpted daily glucose profile (target insulin delivery).
Once the target insulin delivery is determined a meal-related insulin distribution profile is computed from an average response of reprocessed historical events for the particular subj ect.
The feedforward algorithm is used as part of an intensive insulin therapy/pump therapy and allows the control unit 14 to make adjustments due to variations in the subject's glucose-insulin dynamics as well as enables the control unit 14 to compensate for meals. This feedforward algorithm first makes an assumption that non-meal related insulin needs are covered by the basal rate. This basal rate has a fixed profile over the day. Disturbances due to meals are compensated for by insulin doses.
Therefore, in the cycle following the entry of meal information, the unit 14 will make an insulin dosage recommendation of the basal rate when the glucose values remain within a predefined post-prandial glucose range. Unit 14 in the upcoming cycles, will recommend that delivery unit 16 administer meal-related amounts of insulin based on the carbohydrate amount and speed entered by the subject into the unit 14. These meal-related insulin dose sizes are based on the unit's reprocessing of historical data of the subject. Specifically, the dose sizes are determined from the expected carbohydrate intake and the insulin-to-carbohydrate ratio. This intake may be constant or may be dependent based on the meal type or the time-of day. Further assumptions include that insulin pharmacokinetics and pharmacodynamics are initially population based; the duration of the insulin effect is about 4 to about 6 hours; and there is an assumed shape of the insulin effect on the subject illustrated in Fig. 6. It is appreciated that these assumptions are merely guidelines and may vary in accordance with this disclosure. The various parameters are further illustrated in Fig. 8. The insulin effect curve is normalized to one.
Further, the glucose lowering effect of a given insulin dose profile is calculated as the convolution of the insulin profile and the insulin effect curve, multiplied by the insulin sensitivity.
Unit 14 ignores the meal intake and any meal related insulin doses (except postprandial rise profile). Further, unit 14 reacts on the deviation of the predicted glucose concentration from the target range. Any insulin administered in excess of the basal need is expected to lower the glucose concentration and any insulin deficit is expected to raise the glucose concentration. Unit 14 estimates the expected drop / rise of glucose from the excess / deficit insulin, the normalized insulin effect, and the insulin sensitivity. The glucose target range can allow for a postprandial rise profile.
The feedforward algorithm of unit 14 is used to determine meal compensation/
dosing by equation (4):
(4) Dose = carbohydrates * insulin-to-carb-ratio * a",ea~ rye - intercept Wherein: Dose = Total insulin dose carbohydrates = grams of carbohydrates insulin-to-Garb-ratio = Insulin to Carbohydrate Ratio ameal cyPe - meal dependent scaling factor (meal compensatory intercept = intercept to allow a linear fit for sizes of the meals The dose is distributed according to a predefined profile dependent on the user-input of carbohydrate amount and preferably the speed of the meal. The insulin distribution ranges from one to five doses depending on the meal size. It is appreciated, however, that the insulin distribution may vary to compensate for different meal speeds.
Further, as shown in Fig. 7, the meal type is generally broken into meal type (breakfast, lunch, dinner, and snack), assuming that breakfast generally requires a relatively larger insulin dose than, for example, lunch, size (amount of carbohydrates), speed (glycemic index or composition: carbohydrates/protein/fat) as well as the time of the meal. It is also appreciated that the intercept is often set close to zero. This intercept, however, is used as a way to initially under deliver insulin, or to set a threshold level of a meal to initiate the delivery of insulin to the subject.
There may also be constraints, which are defined by the equation (5):
(5) infusion rate > (3 * basal rate.
wherein (3 = a fraction that defines a minimum basal rate.
It is appreciated that (3 ranges from about 0.25 to about 0.5. Preferably, (3 is 0.5. This constraint is generally used for overnight and is used to minimize excessive production of glucose from the liver. It is anticipated that the constraint can be violated if a large insulin dose has been administered recently, as well as when the subject is exercising. It is appreciated that this constraint is merely a guideline, and may vary in accordance with this disclosure.
In addition to sensor, delivery unit, and control unit, the system of the present invention may comprise additional components, which can be assembled in different ways. Non-limiting examples of additional components include: a feedback unit, a data processor unit, a communication unit, and a power source unit. These components can be assembled in one single device, or they can be discrete devices that communicate with each other through wired or wireless means (IR link or RF
link). A suitable data processor unit may be, for example, a microprocessor, a portable laptop computer, or a mainframe computer. The communication unit or units can be of the type of a serial port, a RF port, an IR port, an ultrasound mode, or any number of commercially available communication units. The power source can be solar power, battery power (throw away or rechargeable), conventional AC
power, or mechanical power in accordance with this disclosure.
Example 1:
As shown in Fig. 2, glucose was traced for a subject during a 24 hour control day with limited activity and three meals. The first meal is shown by the vertical line A at 10:00, the second meal is shown by the vertical line B at 14:00 and the third meal is shown by the vertical line C at 18:00. The glucose value target range is shown by the vertical line D at 60mg/dL and line E at 250 mg/DL. The nominal target glucose value for the entire period was 120 mg/dL.
Referring now to Fig. 3, glucose concentration (average +/- one standard deviation) was plotted for 22 subjects, who were each controlled for one day.
The meal dose was a single bolus at the time of the meal as shown by letters A,B,C, respectively and was based on the subject's insulin rules for the number of grams of carbohydrates in the meal. Lines D and E illustrate the glucose value target range. In addition, as shown in parenthesis F, the glucose concentration of the subjects was plotted from 0:00 to 8:00 before implementation of the system 10 in accordance with the present invention.
The parameters for the algorithm were composed of a set of population-based parameters and a set of individualized parameters based on the subjects' insulin therapy rules and logbook information. In this experiment, no adaptation to previous high-density glucose or insulin data was employed. Presumably better glycemic control could be achieved after adapting the insulin therapy based on the review of several days of algorithmic control.
Fig. 4 displays the glucose concentration (average +/- one standard deviation) was plotted from a total of 30 experiments from 12 subjects, who were each controlled for at least one day. The meal doses were boluses beginning ten minutes before the time of the meal and were based on the computed insulin-to-carbohydrate ratios determined from the analysis of prior logbook data or control experiment data.
The meals were of a fixed composition so that 60% of the calories in each meal came from carbohydrates.
Although the invention has been described in detail with reference to a preferred embodiment, variations and modifications exist within the scope and spirit of the invention as described and defined in the following claims.
Patent No. 5,174,291. A device based on ultrafiltration is described in U.S.
Patent No. 4,777,953. An example of an implantable sensor is disclosed in U.S. Patent No.
6,049,727.
Further, non-invasive sensors are suitable in accordance with this disclosure.
Non-limiting examples of such known sensors include GLUCOWATCH~' Biographer, commercially available from Cygnus, Inc., Redwood City, CA., as well as sensors disclosed in U.S. Patent Nos. 5,730,714, 5,222,496, and 6,061,582.
It is appreciated that sensor 16 can be any one of a variety of i~x vivo or in vitro sensors in accordance with this disclosure. Since samples are drawn from a subject frequently, it is preferred that sensor 16 be implanted in the subject, such as the CGMS as described above.
Sensor 16 does not generally produce a glucose reading instantaneously, but rather, a period of time elapses between the time that a sample is extracted from the subject and the time that the glucose measurement is available from use by unit 14.
This time delay can range from about 1 minute to about 45 minutes, more typically from about 5 minutes to about 30 minutes, and most typically, the time delay for the glucose measurement is about 5 to about 15 minutes. System of the present invention recognizes that this time delay exists and control unit 14 is formed to compensate, or make corrections for the delay. It is also appreciated that a sensor may be used in the system of the present invention, which reduces or even eliminates this time delay.
Control unit 14, is formed to predict the current glucose value of the subject based upon the delayed glucose reading, the history of insulin infusions, the basal requirement, and the insulin sensitivity of the subject. Insulin sensitivity is defined herein as the expected drop of glucose concentration when lU of insulin is administered to the subject. It is understood that insulin sensitivity is individual to the subject and is determined over a period of time.
Unit 14 includes a processor unit that executes an algorithm to determine an insulin dosage recommendation and a communication unit that forwards that recommendation of the processor unit to the delivery unit 12. It is appreciated that non-limiting examples of suitable processor units include microprocessors, portable laptop computers, or mainframe computers. The communication unit or units can be of the type of a serial port, a RF port, an IR port, an ultrasound mode, or any number of commercially available communication units. Non-limiting examples of power sources suitable to power the processing and communication units can be solar power, battery power (throw away or rechargeable), conventional AC power, or mechanical power in accordance with this disclosure. It is appreciated that processor unit and communication unit can be assembled in one single device, or they can be discrete devices that communicate with each other through wired or wireless means (IR
link or RF link).
The processor unit of control unit 14 is a microprocessor. It is appreciated that the microprocessor may be any number of commercially available microprocessors.
A non-limiting example of a suitable microprocessor includes a personal digital assistant (PDA) that includes a display. The display enables the subject to input data and review data from unit 14. Non-limiting examples of data displayed by unit includes the glucose values, insulin doses and their times of administration, the carbohydrates consumed or to be consumed and the times they are consumed, and exercise performed or to be performed, the duration of the exercise, and the intensity of the exercise. In addition, non-limiting examples of the display include a data input unit with a visual display unit and/or an auditory/vibratory feedback unit in accordance with this disclosure. It is appreciated that data can also be inputted via a keyboard.
In addition, to processor unit and communication unit, the control unit 14 of the present invention preferably includes a memory unit. The memory unit stores the algorithms, the glucose concentrations, the amount of insulin administered, the times of administration, the carbohydrates consumed, the times the carbohydrates were consumed, and the duration and intensity of any exercise performed by the subject.
The memory unit is formed with memory components, non-limiting examples of which include a RAM unit, a disk drive unit, a hard disk drive unit, a tape drive unit, . CA 02394900 2002-07-24 or other data storage means, which are well known in the art. It is appreciated that the memory unit may be a discrete component rather than integral with the processor and communication units.
The memory unit can communicate with the processor and communication units through wired or wireless means (IR link or RF link). The processor unit of the control unit 14 predicts an expected drop in glucose over time after accounting for the time delay in the sensor using a feedback algorithm that is stored in the memory unit.
Based upon that drop, the processor unit makes a recommendation for the administration of additional insulin to the subject to reach a pre-determined target glucose level at a pre-determined time in the future. In preferred embodiments, as will be discussed hereafter; the processor unit also uses a feedforward algorithm stored in the memory unit that allows adjustment due to variations in a subject's glucose-insulin dynamics as well as meal related information. See Figs. 5, 7, and 8.
In at least one embodiment of the present invention, the control unit 14 operates using both levels of algorithms. The first level is a basal rate control or a feedback algorithm stored in the memory unit. The second level is a compensation control for meals and/or exercise or a feedforward algorithm that is also stored in the memory unit. See Figs. 5, 7 and 8. It is appreciated that the feedback algorithm operates on the assumption that there exists an insulin basal rate for a subject that is required to maintain a steady-state glucose level at a specified therapy level. This pre-determined basal rate is used by the feedback algorithm in making its insulin dosage recommendations. The feedback algorithm excludes insulin equivalents for meals and exercise from the prediction of a future glucose value.
Recommendations for doses of insulin to cover meals are made based upon the subject's experience (carbohydrate/insulin ratio or fixed dose) and lie outside of the feedback algorithms used by the control unit 14.
In the feedforward algorithm, the administered insulin dose is expected to ideally flatten or counteract the carbohydrates taken in the meal (or at least stay within a predetermined range of glucose values over a period of time). The feedforward algorithm reprocesses historical data of the subject to make a determination of an appropriate insulin dosage for categorized meals. Likewise, the insulin dose reduction due to exercise is based on historical data to determine the appropriate insulin dose reduction for categorized exercise. It is appreciated, that the feedback algorithm used by the processor unit of the control unit 14 does not see the effects of these feedforward meal-related insulin doses or exercise-related insulin reductions.
The control unit 14 uses the feedback algorithm in a predictive model to predict the future glucose level of a subject at a pre-determined time. The feedback algorithm is illustrated by equations (1-3). First, equation (1) is used to predict a current glucose value (for an expected delay in glucose measurement) as follows:
(1) InaulinDunriinn G(i + 1) = G(i) +' InsuTrac i InsuGluDro i + Basal Re uirement i Sensitivi ~ ) * P( )) q ( )~
i=i Wherein G (i) = glucose concentration i cycles in the past i = cycle InsuTrace (i) - series of pulses of insulin that were administered in the past (excluding meal-related insulin doses and exercise-related insulin reductions) normalized InsuGluDrop (i) = amount that the glucose is expected to drop on the next cycle due to insulin delivered at times in the past OT = time interval between cycles (in minutes) Basal Requirement (i) = amount of insulin required in the i'th cycle to maintain current glucose in the absence of disturbances Sensitivity = expected magnitude of glucose drop for lU of insulin.
Next, control unit 14 predicts a future change in glucose level in accordance with equation (2):
(2) aG = -(TotalInsuRemain - BasalReq) * Sensitivity Wherein 0G = expected future change in glucose levels TotalInsuRemain = expected amount of insulin remaining in the subject's system (excluding meal-related doses and exercise dose reductions) BasalReq = how much insulin the subject is estimated to need S Control unit 14 then makes a recommended insulin dose to reach the target range of glucose level in full time of the insulin action using equation (3):
(3) InsuRecommend = [G (0) + OG - Target] / Sensitivity + BasalNeed PerCycle Wherein InsuRecommend = recommended insulin dosage G (0) = predicted current glucose level Target = glucose target level BasalNeedPerCycle = basal requirements of the subject during each cycle The recommended dosage is rounded to the nearest 0.05 U to 0.1 U resolution.
Tt is appreciated that the recommended dosage need not be rounded or may be rounded to a different level of precision in accordance with the disclosure.
The recommendation of the control unit 14 resulting from the feedback algorithm is transmitted to the delivery unit 12. The transmission can take place over a fixed wire or preferably via telemetric connection (IR link or RF link). It is appreciated that the transmission can take place using any number of wired or wireless means in accordance with this disclosure. It is also possible that the subject may operate the delivery unit 12 themselves, such as an insulin pump outfitted with a transmission unit that transmits the administered insulin dose along with the time of administration to the control unit 14.
The feedforward algorithm is part of an insulin adaptation model used by unit 14 that allows the system to analyze past data and to make modifications to the existing therapy based upon that data. This adaptation model performs the function of an event handler 20, a meal compensator 22, a basal controller 24, and a dose nullifier 26. See Fig. 5. In practice, the adaptation model again assumes a basal insulin requirement and an insulin sensitivity, which is specific to the subject. It is appreciated that the subject initially inputs information on meals and exercise into control unit 14 based upon personal history. See Fig. 5, which is a schematic illustration of the feedforward algorithm of the adaptation model. The adaptation model uses this subject-provided data as well as the historical data gathered by the unit 14 to correct or refine the subject-provided data to make a recommended therapy as to the distribution and amount of insulin for meal related doses as well as exercise.
Thus, the adaptation model uses historical data for post processing to develop updated settings and functions for the particular subject. Specifically, the historical data is reprocessed by first mathematically removing all insulin from the dataset except for the particular subject's basal requirement of insulin. When the correct basal insulin rates) are applied, it is expected that the subject's glucose levels will remain nearly flat while fasting and for short pre-prandial periods. During meals, the glucose levels progressively increase with time and only during exercise is a decrease anticipated. Second, the distribution and amount of insulin doses are determined that provide a flat or sculpted daily glucose profile (target insulin delivery).
Once the target insulin delivery is determined a meal-related insulin distribution profile is computed from an average response of reprocessed historical events for the particular subj ect.
The feedforward algorithm is used as part of an intensive insulin therapy/pump therapy and allows the control unit 14 to make adjustments due to variations in the subject's glucose-insulin dynamics as well as enables the control unit 14 to compensate for meals. This feedforward algorithm first makes an assumption that non-meal related insulin needs are covered by the basal rate. This basal rate has a fixed profile over the day. Disturbances due to meals are compensated for by insulin doses.
Therefore, in the cycle following the entry of meal information, the unit 14 will make an insulin dosage recommendation of the basal rate when the glucose values remain within a predefined post-prandial glucose range. Unit 14 in the upcoming cycles, will recommend that delivery unit 16 administer meal-related amounts of insulin based on the carbohydrate amount and speed entered by the subject into the unit 14. These meal-related insulin dose sizes are based on the unit's reprocessing of historical data of the subject. Specifically, the dose sizes are determined from the expected carbohydrate intake and the insulin-to-carbohydrate ratio. This intake may be constant or may be dependent based on the meal type or the time-of day. Further assumptions include that insulin pharmacokinetics and pharmacodynamics are initially population based; the duration of the insulin effect is about 4 to about 6 hours; and there is an assumed shape of the insulin effect on the subject illustrated in Fig. 6. It is appreciated that these assumptions are merely guidelines and may vary in accordance with this disclosure. The various parameters are further illustrated in Fig. 8. The insulin effect curve is normalized to one.
Further, the glucose lowering effect of a given insulin dose profile is calculated as the convolution of the insulin profile and the insulin effect curve, multiplied by the insulin sensitivity.
Unit 14 ignores the meal intake and any meal related insulin doses (except postprandial rise profile). Further, unit 14 reacts on the deviation of the predicted glucose concentration from the target range. Any insulin administered in excess of the basal need is expected to lower the glucose concentration and any insulin deficit is expected to raise the glucose concentration. Unit 14 estimates the expected drop / rise of glucose from the excess / deficit insulin, the normalized insulin effect, and the insulin sensitivity. The glucose target range can allow for a postprandial rise profile.
The feedforward algorithm of unit 14 is used to determine meal compensation/
dosing by equation (4):
(4) Dose = carbohydrates * insulin-to-carb-ratio * a",ea~ rye - intercept Wherein: Dose = Total insulin dose carbohydrates = grams of carbohydrates insulin-to-Garb-ratio = Insulin to Carbohydrate Ratio ameal cyPe - meal dependent scaling factor (meal compensatory intercept = intercept to allow a linear fit for sizes of the meals The dose is distributed according to a predefined profile dependent on the user-input of carbohydrate amount and preferably the speed of the meal. The insulin distribution ranges from one to five doses depending on the meal size. It is appreciated, however, that the insulin distribution may vary to compensate for different meal speeds.
Further, as shown in Fig. 7, the meal type is generally broken into meal type (breakfast, lunch, dinner, and snack), assuming that breakfast generally requires a relatively larger insulin dose than, for example, lunch, size (amount of carbohydrates), speed (glycemic index or composition: carbohydrates/protein/fat) as well as the time of the meal. It is also appreciated that the intercept is often set close to zero. This intercept, however, is used as a way to initially under deliver insulin, or to set a threshold level of a meal to initiate the delivery of insulin to the subject.
There may also be constraints, which are defined by the equation (5):
(5) infusion rate > (3 * basal rate.
wherein (3 = a fraction that defines a minimum basal rate.
It is appreciated that (3 ranges from about 0.25 to about 0.5. Preferably, (3 is 0.5. This constraint is generally used for overnight and is used to minimize excessive production of glucose from the liver. It is anticipated that the constraint can be violated if a large insulin dose has been administered recently, as well as when the subject is exercising. It is appreciated that this constraint is merely a guideline, and may vary in accordance with this disclosure.
In addition to sensor, delivery unit, and control unit, the system of the present invention may comprise additional components, which can be assembled in different ways. Non-limiting examples of additional components include: a feedback unit, a data processor unit, a communication unit, and a power source unit. These components can be assembled in one single device, or they can be discrete devices that communicate with each other through wired or wireless means (IR link or RF
link). A suitable data processor unit may be, for example, a microprocessor, a portable laptop computer, or a mainframe computer. The communication unit or units can be of the type of a serial port, a RF port, an IR port, an ultrasound mode, or any number of commercially available communication units. The power source can be solar power, battery power (throw away or rechargeable), conventional AC
power, or mechanical power in accordance with this disclosure.
Example 1:
As shown in Fig. 2, glucose was traced for a subject during a 24 hour control day with limited activity and three meals. The first meal is shown by the vertical line A at 10:00, the second meal is shown by the vertical line B at 14:00 and the third meal is shown by the vertical line C at 18:00. The glucose value target range is shown by the vertical line D at 60mg/dL and line E at 250 mg/DL. The nominal target glucose value for the entire period was 120 mg/dL.
Referring now to Fig. 3, glucose concentration (average +/- one standard deviation) was plotted for 22 subjects, who were each controlled for one day.
The meal dose was a single bolus at the time of the meal as shown by letters A,B,C, respectively and was based on the subject's insulin rules for the number of grams of carbohydrates in the meal. Lines D and E illustrate the glucose value target range. In addition, as shown in parenthesis F, the glucose concentration of the subjects was plotted from 0:00 to 8:00 before implementation of the system 10 in accordance with the present invention.
The parameters for the algorithm were composed of a set of population-based parameters and a set of individualized parameters based on the subjects' insulin therapy rules and logbook information. In this experiment, no adaptation to previous high-density glucose or insulin data was employed. Presumably better glycemic control could be achieved after adapting the insulin therapy based on the review of several days of algorithmic control.
Fig. 4 displays the glucose concentration (average +/- one standard deviation) was plotted from a total of 30 experiments from 12 subjects, who were each controlled for at least one day. The meal doses were boluses beginning ten minutes before the time of the meal and were based on the computed insulin-to-carbohydrate ratios determined from the analysis of prior logbook data or control experiment data.
The meals were of a fixed composition so that 60% of the calories in each meal came from carbohydrates.
Although the invention has been described in detail with reference to a preferred embodiment, variations and modifications exist within the scope and spirit of the invention as described and defined in the following claims.
Claims (23)
1. A system for providing glycemic control to a subject, the system comprising:
an insulin delivery unit, a glucose sensor, and a control unit including a processor unit that receives glucose value readings from the glucose sensor, executes an algorithm that predicts a glucose value at a pre-determined time in the future, compares that predicted glucose value to a pre-determined glucose value range, and determines a corrective amount of insulin to be administered when the predictive glucose value lies outside of the pre-determined glucose value range and a communication unit that transmits the corrective amount to the delivery unit.
an insulin delivery unit, a glucose sensor, and a control unit including a processor unit that receives glucose value readings from the glucose sensor, executes an algorithm that predicts a glucose value at a pre-determined time in the future, compares that predicted glucose value to a pre-determined glucose value range, and determines a corrective amount of insulin to be administered when the predictive glucose value lies outside of the pre-determined glucose value range and a communication unit that transmits the corrective amount to the delivery unit.
2. The system of claim 1 wherein the control unit is formed to accept data from the subject.
3. The system of claim 2 wherein the data includes information on size and type of a meal to be ingested and anticipated duration and intensity of exercise.
4. The system of claim 3 wherein the control unit includes a memory unit formed to store the data provided by the subject.
5. The system of claim 4 wherein the memory unit also is formed to store an algorithm that utilizes the stored data and the processor unit is formed to execute the algorithm to determine the predictive glucose value.
6. The system of claim 1 wherein the sensor is a semi-continuous glucose-sensing unit.
7. The system of claim 1 wherein the algorithm includes the following equation:
.DELTA.G = -(TotalInsuRemain - BasalReq) * Sensitivity wherein .DELTA.G = future change in glucose levels at a pre-determined time TotalInsuRemain = amount of insulin remaining in the subject's system at a current time, and BasalReq = how much insulin the subject is estimated to need to maintain the current glucose level, and Sensitivity = Insulin sensitivity.
.DELTA.G = -(TotalInsuRemain - BasalReq) * Sensitivity wherein .DELTA.G = future change in glucose levels at a pre-determined time TotalInsuRemain = amount of insulin remaining in the subject's system at a current time, and BasalReq = how much insulin the subject is estimated to need to maintain the current glucose level, and Sensitivity = Insulin sensitivity.
8. The system of claim 7 further comprising a memory unit that is formed to store the algorithm and data, the data including glucose value readings from the glucose sensor, predicted glucose values, the pre-determined glucose value range, and corrective amounts of insulin.
9. The system of claim 8 wherein the memory unit is formed to store a feedforward algorithm that utilizes at least a portion of the data stored in the memory to compensate for meals.
10. The system of claim 9 wherein the feedforward algorithm includes the following equation:
Dose = carbohydrates * insulin-to-carb-ratio * .alpha.meal type - intercept wherein: Dose = Total insulin dose carbohydrates = grams of carbohydrates insulin-to-carb-ratio = Insulin to Carbohydrate Ratio .alpha.meal type = meal dependent scaling factor intercept = intercept to allow a linear fit for sizes of the meals
Dose = carbohydrates * insulin-to-carb-ratio * .alpha.meal type - intercept wherein: Dose = Total insulin dose carbohydrates = grams of carbohydrates insulin-to-carb-ratio = Insulin to Carbohydrate Ratio .alpha.meal type = meal dependent scaling factor intercept = intercept to allow a linear fit for sizes of the meals
11. A system for providing glycemic control to a subject comprising:
a sensor formed to conduct a glucose measurement of a subject, a control unit including a processor unit that is formed to accept data from the subject on insulin sensitivity and basal rate, to execute an algorithm that generates a predictive value of the subject's glucose level at a predetermined time in the future based upon the glucose measurement from the sensor and the data, and to compute a corrective action when the predictive value lies outside of a predetermined target range, and an insulin delivery unit in communication with the control unit, the delivery unit being formed to administer automatically a dosage of insulin to the subject based upon the computed corrective action of the control unit.
a sensor formed to conduct a glucose measurement of a subject, a control unit including a processor unit that is formed to accept data from the subject on insulin sensitivity and basal rate, to execute an algorithm that generates a predictive value of the subject's glucose level at a predetermined time in the future based upon the glucose measurement from the sensor and the data, and to compute a corrective action when the predictive value lies outside of a predetermined target range, and an insulin delivery unit in communication with the control unit, the delivery unit being formed to administer automatically a dosage of insulin to the subject based upon the computed corrective action of the control unit.
12. The system of claim 11, wherein the control unit is formed to accept data from the subject regarding size and type of a meal to be ingested and anticipated duration and intensity of exercise.
13. The system of claim 11 wherein the algorithm includes the following equation:
.DELTA.G = -(TotalInsuRemain - BasalReq) * Sensitivity wherein .DELTA.G = future change in glucose levels at a pre-determined time TotalInsuRemain = amount of insulin remaining in the subject's system at a current time, and BasalReq = how much insulin the subject is estimated to need at time, and Sensitivity = Insulin sensitivity.
.DELTA.G = -(TotalInsuRemain - BasalReq) * Sensitivity wherein .DELTA.G = future change in glucose levels at a pre-determined time TotalInsuRemain = amount of insulin remaining in the subject's system at a current time, and BasalReq = how much insulin the subject is estimated to need at time, and Sensitivity = Insulin sensitivity.
14. The system of claim 11, wherein the control unit includes a memory that is formed to store data of the glucose concentrations as well as the time and amount of previously administered insulin.
15. The system of claim 14, wherein the memory is formed to store data regarding size and type of a meal to be ingested and anticipated duration and intensity of exercise of the subject.
16. A system for providing glycemic control to a subject, the system comprising:
means for delivering insulin to a subject, means for determining a glucose value from the subject, and a control unit including a processor unit that is formed to compare the glucose value to a pre-determined glucose value range, to determine a corrective amount of insulin to be administered when the predictive glucose value lies outside of the pre-determined glucose value range, and to transmit the corrective amount to the delivering means.
means for delivering insulin to a subject, means for determining a glucose value from the subject, and a control unit including a processor unit that is formed to compare the glucose value to a pre-determined glucose value range, to determine a corrective amount of insulin to be administered when the predictive glucose value lies outside of the pre-determined glucose value range, and to transmit the corrective amount to the delivering means.
17. A system for predicting a future glucose value of a subject at a predetermined time, the system comprising a control unit that comprises:
a processor unit formed to predict the future glucose value with an algorithm .DELTA.G = -(TotalInsuRemain - BasalReq) * Sensitivity wherein .DELTA.G = future change in glucose levels at a pre-determined time, TotalInsuRemain = amount of insulin remaining in the subject's system at a current time, and BasalReq = how much insulin the subject is estimated to need to maintain the current glucose level, and Sensitivity = Insulin sensitivity.
a processor unit formed to predict the future glucose value with an algorithm .DELTA.G = -(TotalInsuRemain - BasalReq) * Sensitivity wherein .DELTA.G = future change in glucose levels at a pre-determined time, TotalInsuRemain = amount of insulin remaining in the subject's system at a current time, and BasalReq = how much insulin the subject is estimated to need to maintain the current glucose level, and Sensitivity = Insulin sensitivity.
18. The system of claim 17 wherein the processor is further formed to compensate for meals and exercise with a feedforward algorithm Dose = carbohydrates * insulin-to-carb-ratio * .alpha.meal type - intercept wherein Dose = Total insulin dose; carbohydrates = grams of carbohydrates, insulin-to-carb-ratio = Insulin to Carbohydrate Ratio, .alpha.meal type = meal dependent scaling factor, and intercept to allow a linear fit for sizes of the meals.
19. The system of claim 18 wherein the processor is further formed to provide a constraint to the feedforward algorithm, wherein the constraint is defined by the following equation: infusion rate >=.beta. * basal rate, wherein .beta.
= a fraction that defines a minimum basal rate.
= a fraction that defines a minimum basal rate.
20. The system of claim 17 wherein the processor makes a recommended insulin dose to reach a target range in full time of the insulin action according to the following equation:
InsuRecommend = [G(0) + .DELTA.G - Target]/Sensitivity + BasalNeed PerCycle wherein InsuRecommend = recommended insulin dosage, G(0) = predicted current glucose level, Target = glucose target level, and BasalNeedPerCycle =
basal requirements of the subject during each cycle.
InsuRecommend = [G(0) + .DELTA.G - Target]/Sensitivity + BasalNeed PerCycle wherein InsuRecommend = recommended insulin dosage, G(0) = predicted current glucose level, Target = glucose target level, and BasalNeedPerCycle =
basal requirements of the subject during each cycle.
21. The system of claim 17 wherein the processor predicts a current glucose value using the following equation:
wherein G (i) = glucose concentration i cycles in the past, i = cycle, InsuTrace(i) = series of pulses of insulin that were administered in the past (excluding meal-related insulin doses and exercise-related insulin reductions) normalized, InsulinDuration = total time action of insulin, InsuGluDrop(i) =
amount that the glucose is expected to drop on the next cycle due to insulin delivered at times in the past, .DELTA.T = time interval between cycles (in minutes), Basal Requirement (i) =
amount of insulin required in the i'th cycle to maintain current glucose in the absence of disturbances, and Sensitivity = expected magnitude of glucose drop for lU
of insulin.
wherein G (i) = glucose concentration i cycles in the past, i = cycle, InsuTrace(i) = series of pulses of insulin that were administered in the past (excluding meal-related insulin doses and exercise-related insulin reductions) normalized, InsulinDuration = total time action of insulin, InsuGluDrop(i) =
amount that the glucose is expected to drop on the next cycle due to insulin delivered at times in the past, .DELTA.T = time interval between cycles (in minutes), Basal Requirement (i) =
amount of insulin required in the i'th cycle to maintain current glucose in the absence of disturbances, and Sensitivity = expected magnitude of glucose drop for lU
of insulin.
22. The system of claim 17 wherein the control unit recommends an insulin dose to compensate for meals of a subject, the control unit comprises:
a processor formed to compensate for meals with a feedforward algorithm Dose = carbohydrates * insulin-to-carb-ratio * .alpha.meal type - intercept wherein Dose = Total insulin dose, carbohydrates = grams of carbohydrates, insulin-to-carb-ratio = Insulin to Carbohydrate Ratio, .alpha.meal type = meal dependent scaling factor, and intercept to allow a linear fit for sizes of the meals.
a processor formed to compensate for meals with a feedforward algorithm Dose = carbohydrates * insulin-to-carb-ratio * .alpha.meal type - intercept wherein Dose = Total insulin dose, carbohydrates = grams of carbohydrates, insulin-to-carb-ratio = Insulin to Carbohydrate Ratio, .alpha.meal type = meal dependent scaling factor, and intercept to allow a linear fit for sizes of the meals.
23. The system of claim 22 wherein the processor is further formed to provide a constraint to the feedforward algorithm, wherein the constraint is defined by the following equation: infusion rate >= .beta. * basal rate, wherein .beta. = a fraction that defines a minimum basal rate.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/918,623 US6544212B2 (en) | 2001-07-31 | 2001-07-31 | Diabetes management system |
| US09/918,623 | 2001-07-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2394900A1 CA2394900A1 (en) | 2003-01-31 |
| CA2394900C true CA2394900C (en) | 2006-02-14 |
Family
ID=25440684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002394900A Expired - Lifetime CA2394900C (en) | 2001-07-31 | 2002-07-24 | Diabetes management system |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6544212B2 (en) |
| EP (1) | EP1281351B8 (en) |
| JP (2) | JP4231253B2 (en) |
| AT (1) | ATE413654T1 (en) |
| CA (1) | CA2394900C (en) |
| DE (1) | DE60229693D1 (en) |
| ES (1) | ES2316506T3 (en) |
Families Citing this family (800)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6413410B1 (en) | 1996-06-19 | 2002-07-02 | Lifescan, Inc. | Electrochemical cell |
| AUPN661995A0 (en) | 1995-11-16 | 1995-12-07 | Memtec America Corporation | Electrochemical cell 2 |
| US6863801B2 (en) * | 1995-11-16 | 2005-03-08 | Lifescan, Inc. | Electrochemical cell |
| SE9700384D0 (en) * | 1997-02-04 | 1997-02-04 | Biacore Ab | Analytical method and apparatus |
| US9155496B2 (en) | 1997-03-04 | 2015-10-13 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
| US7899511B2 (en) * | 2004-07-13 | 2011-03-01 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
| US7657297B2 (en) | 2004-05-03 | 2010-02-02 | Dexcom, Inc. | Implantable analyte sensor |
| US6558351B1 (en) * | 1999-06-03 | 2003-05-06 | Medtronic Minimed, Inc. | Closed loop system for controlling insulin infusion |
| US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8480580B2 (en) | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
| US6949816B2 (en) | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
| DK1144028T3 (en) | 1998-11-30 | 2004-10-18 | Novo Nordisk As | A system for assisting a user during medical self-treatment, wherein said self-treatment comprises a plurality of actions |
| US6669663B1 (en) * | 1999-04-30 | 2003-12-30 | Medtronic, Inc. | Closed loop medicament pump |
| US7806886B2 (en) * | 1999-06-03 | 2010-10-05 | Medtronic Minimed, Inc. | Apparatus and method for controlling insulin infusion with state variable feedback |
| US6562001B2 (en) | 2000-01-21 | 2003-05-13 | Medtronic Minimed, Inc. | Microprocessor controlled ambulatory medical apparatus with hand held communication device |
| US20030060765A1 (en) * | 2000-02-16 | 2003-03-27 | Arthur Campbell | Infusion device menu structure and method of using the same |
| DZ3338A1 (en) * | 2000-03-29 | 2001-10-04 | Univ Virginia | METHOD, SYSTEM AND COMPUTER PROGRAM FOR EVALUATING GLYCEMIC REGULATION OF DIABETES FROM AUTOMATICALLY CONTROLLED DATA |
| US6572545B2 (en) * | 2000-09-22 | 2003-06-03 | Knobbe, Lim & Buckingham | Method and apparatus for real-time control of physiological parameters |
| US20120191052A1 (en) * | 2000-10-06 | 2012-07-26 | Ip Holdings, Inc. | Intelligent activated skin patch system |
| US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
| EP1397068A2 (en) | 2001-04-02 | 2004-03-17 | Therasense, Inc. | Blood glucose tracking apparatus and methods |
| JP2004538078A (en) * | 2001-08-20 | 2004-12-24 | インバネス・メディカル・リミテッド | Wireless diabetes management device and method of using wireless diabetes management device |
| US6740072B2 (en) * | 2001-09-07 | 2004-05-25 | Medtronic Minimed, Inc. | System and method for providing closed loop infusion formulation delivery |
| US6827702B2 (en) | 2001-09-07 | 2004-12-07 | Medtronic Minimed, Inc. | Safety limits for closed-loop infusion pump control |
| US8152789B2 (en) * | 2001-10-23 | 2012-04-10 | Medtronic Minimed, Inc. | System and method for providing closed loop infusion formulation delivery |
| CN1920548B (en) * | 2001-10-10 | 2013-05-29 | 生命扫描有限公司 | Method for manufacturing electrochemical cell |
| US10080529B2 (en) | 2001-12-27 | 2018-09-25 | Medtronic Minimed, Inc. | System for monitoring physiological characteristics |
| US9282925B2 (en) * | 2002-02-12 | 2016-03-15 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
| US9247901B2 (en) | 2003-08-22 | 2016-02-02 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
| US8260393B2 (en) | 2003-07-25 | 2012-09-04 | Dexcom, Inc. | Systems and methods for replacing signal data artifacts in a glucose sensor data stream |
| US8010174B2 (en) * | 2003-08-22 | 2011-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
| US20030212379A1 (en) * | 2002-02-26 | 2003-11-13 | Bylund Adam David | Systems and methods for remotely controlling medication infusion and analyte monitoring |
| US20080172026A1 (en) | 2006-10-17 | 2008-07-17 | Blomquist Michael L | Insulin pump having a suspension bolus |
| US6852104B2 (en) * | 2002-02-28 | 2005-02-08 | Smiths Medical Md, Inc. | Programmable insulin pump |
| GB0206792D0 (en) * | 2002-03-22 | 2002-05-01 | Leuven K U Res & Dev | Normoglycemia |
| US20040068230A1 (en) | 2002-07-24 | 2004-04-08 | Medtronic Minimed, Inc. | System for providing blood glucose measurements to an infusion device |
| SE526943C2 (en) * | 2002-08-26 | 2005-11-22 | Indevex Ab | food composition |
| US7404796B2 (en) * | 2004-03-01 | 2008-07-29 | Becton Dickinson And Company | System for determining insulin dose using carbohydrate to insulin ratio and insulin sensitivity factor |
| US7727181B2 (en) * | 2002-10-09 | 2010-06-01 | Abbott Diabetes Care Inc. | Fluid delivery device with autocalibration |
| AU2003279237A1 (en) | 2002-10-09 | 2004-05-04 | Therasense, Inc. | Fluid delivery device, system and method |
| US7993108B2 (en) * | 2002-10-09 | 2011-08-09 | Abbott Diabetes Care Inc. | Variable volume, shape memory actuated insulin dispensing pump |
| DK1551282T3 (en) * | 2002-10-09 | 2016-02-22 | Bodymedia Inc | DEVICE FOR RECEIVING, RECEIVING, DETERMINING AND DISPLAYING PHYSIOLOGICAL AND CONTEXTUAL INFORMATION ON A HUMAN |
| US7811231B2 (en) | 2002-12-31 | 2010-10-12 | Abbott Diabetes Care Inc. | Continuous glucose monitoring system and methods of use |
| US8771183B2 (en) | 2004-02-17 | 2014-07-08 | Abbott Diabetes Care Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
| US9872890B2 (en) * | 2003-03-19 | 2018-01-23 | Paul C. Davidson | Determining insulin dosing schedules and carbohydrate-to-insulin ratios in diabetic patients |
| JP4800928B2 (en) * | 2003-03-19 | 2011-10-26 | ヘブルホワイト、ハリー | Apparatus for periodically adjusting insulin therapy for diabetics and apparatus for adjusting insulin dose parameters for diabetics in an insulin delivery device or in a physician's computer |
| CA2520880A1 (en) * | 2003-04-18 | 2004-11-04 | Insulet Corporation | User interface for infusion pump remote controller and method of using the same |
| US7679407B2 (en) | 2003-04-28 | 2010-03-16 | Abbott Diabetes Care Inc. | Method and apparatus for providing peak detection circuitry for data communication systems |
| US8066639B2 (en) | 2003-06-10 | 2011-11-29 | Abbott Diabetes Care Inc. | Glucose measuring device for use in personal area network |
| US20050055243A1 (en) * | 2003-06-30 | 2005-03-10 | Dave Arndt | Method and apparatus for managing data received from a medical device |
| US7761130B2 (en) | 2003-07-25 | 2010-07-20 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| US8423113B2 (en) * | 2003-07-25 | 2013-04-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
| US20190357827A1 (en) | 2003-08-01 | 2019-11-28 | Dexcom, Inc. | Analyte sensor |
| US8761856B2 (en) | 2003-08-01 | 2014-06-24 | Dexcom, Inc. | System and methods for processing analyte sensor data |
| US6931327B2 (en) | 2003-08-01 | 2005-08-16 | Dexcom, Inc. | System and methods for processing analyte sensor data |
| US7519408B2 (en) * | 2003-11-19 | 2009-04-14 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
| US8845536B2 (en) | 2003-08-01 | 2014-09-30 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US8160669B2 (en) | 2003-08-01 | 2012-04-17 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US9135402B2 (en) | 2007-12-17 | 2015-09-15 | Dexcom, Inc. | Systems and methods for processing sensor data |
| US8622905B2 (en) * | 2003-08-01 | 2014-01-07 | Dexcom, Inc. | System and methods for processing analyte sensor data |
| US8626257B2 (en) | 2003-08-01 | 2014-01-07 | Dexcom, Inc. | Analyte sensor |
| US8886273B2 (en) * | 2003-08-01 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
| US20070208245A1 (en) * | 2003-08-01 | 2007-09-06 | Brauker James H | Transcutaneous analyte sensor |
| US7774145B2 (en) | 2003-08-01 | 2010-08-10 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US7925321B2 (en) * | 2003-08-01 | 2011-04-12 | Dexcom, Inc. | System and methods for processing analyte sensor data |
| US8369919B2 (en) * | 2003-08-01 | 2013-02-05 | Dexcom, Inc. | Systems and methods for processing sensor data |
| US7591801B2 (en) * | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
| US8275437B2 (en) * | 2003-08-01 | 2012-09-25 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US20140121989A1 (en) | 2003-08-22 | 2014-05-01 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
| US8233959B2 (en) * | 2003-08-22 | 2012-07-31 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
| US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
| US20050202063A1 (en) * | 2003-08-26 | 2005-09-15 | Ebn International Kft | Food product |
| US8065161B2 (en) | 2003-11-13 | 2011-11-22 | Hospira, Inc. | System for maintaining drug information and communicating with medication delivery devices |
| US9123077B2 (en) | 2003-10-07 | 2015-09-01 | Hospira, Inc. | Medication management system |
| WO2005041022A1 (en) * | 2003-10-24 | 2005-05-06 | Judy Singley | Method, system, and computer program for performing carbohydrate/insulin calculation based upon food weight |
| EP1683058A2 (en) * | 2003-10-29 | 2006-07-26 | Novo Nordisk A/S | Medical advisory system |
| US7299082B2 (en) | 2003-10-31 | 2007-11-20 | Abbott Diabetes Care, Inc. | Method of calibrating an analyte-measurement device, and associated methods, devices and systems |
| US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
| US7787923B2 (en) * | 2003-11-26 | 2010-08-31 | Becton, Dickinson And Company | Fiber optic device for sensing analytes and method of making same |
| US20080197024A1 (en) * | 2003-12-05 | 2008-08-21 | Dexcom, Inc. | Analyte sensor |
| US8425416B2 (en) * | 2006-10-04 | 2013-04-23 | Dexcom, Inc. | Analyte sensor |
| US8287453B2 (en) | 2003-12-05 | 2012-10-16 | Dexcom, Inc. | Analyte sensor |
| US8532730B2 (en) * | 2006-10-04 | 2013-09-10 | Dexcom, Inc. | Analyte sensor |
| EP2239567B1 (en) | 2003-12-05 | 2015-09-02 | DexCom, Inc. | Calibration techniques for a continuous analyte sensor |
| US8425417B2 (en) * | 2003-12-05 | 2013-04-23 | Dexcom, Inc. | Integrated device for continuous in vivo analyte detection and simultaneous control of an infusion device |
| US8364231B2 (en) * | 2006-10-04 | 2013-01-29 | Dexcom, Inc. | Analyte sensor |
| US8364230B2 (en) * | 2006-10-04 | 2013-01-29 | Dexcom, Inc. | Analyte sensor |
| US11633133B2 (en) | 2003-12-05 | 2023-04-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| US8423114B2 (en) | 2006-10-04 | 2013-04-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| EP2316331B1 (en) * | 2003-12-09 | 2016-06-29 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
| US20050182451A1 (en) * | 2004-01-12 | 2005-08-18 | Adam Griffin | Implantable device with improved radio frequency capabilities |
| US7510849B2 (en) * | 2004-01-29 | 2009-03-31 | Glucolight Corporation | OCT based method for diagnosis and therapy |
| US8808228B2 (en) | 2004-02-26 | 2014-08-19 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
| WO2009048462A1 (en) * | 2007-10-09 | 2009-04-16 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
| DE102004011135A1 (en) | 2004-03-08 | 2005-09-29 | Disetronic Licensing Ag | Method and apparatus for calculating a bolus amount |
| JPWO2005106446A1 (en) * | 2004-04-30 | 2008-03-21 | 松下電器産業株式会社 | Blood glucose level measuring device |
| US8792955B2 (en) | 2004-05-03 | 2014-07-29 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US7651845B2 (en) * | 2004-05-13 | 2010-01-26 | The Regents Of The University Of California | Method and apparatus for glucose control and insulin dosing for diabetics |
| JP2005328924A (en) * | 2004-05-18 | 2005-12-02 | Toyama Univ | Blood sugar level prediction device, creating device of blood sugar level prediction model, and program |
| US20050261561A1 (en) * | 2004-05-24 | 2005-11-24 | Christopher W. Jones | Blood testing and therapeutic compound delivery system |
| EP1810185A4 (en) | 2004-06-04 | 2010-01-06 | Therasense Inc | Diabetes care host-client architecture and data management system |
| US7640048B2 (en) | 2004-07-13 | 2009-12-29 | Dexcom, Inc. | Analyte sensor |
| US8452368B2 (en) | 2004-07-13 | 2013-05-28 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US7783333B2 (en) | 2004-07-13 | 2010-08-24 | Dexcom, Inc. | Transcutaneous medical device with variable stiffness |
| US8565848B2 (en) | 2004-07-13 | 2013-10-22 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US7713574B2 (en) | 2004-07-13 | 2010-05-11 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US20060270922A1 (en) | 2004-07-13 | 2006-11-30 | Brauker James H | Analyte sensor |
| US20060016700A1 (en) * | 2004-07-13 | 2006-01-26 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US7254429B2 (en) | 2004-08-11 | 2007-08-07 | Glucolight Corporation | Method and apparatus for monitoring glucose levels in a biological tissue |
| US8036727B2 (en) | 2004-08-11 | 2011-10-11 | Glt Acquisition Corp. | Methods for noninvasively measuring analyte levels in a subject |
| EP3101572A1 (en) | 2004-10-07 | 2016-12-07 | Novo Nordisk A/S | Method for self-management of a disease |
| US20080171913A1 (en) * | 2004-11-15 | 2008-07-17 | Novo Nordisk A/S | Method and Apparatus for Monitoring Long Term and Short Term Effects of a Treatment |
| US7869851B2 (en) | 2004-12-23 | 2011-01-11 | Roche Diagnostics Operations, Inc. | System and method for determining insulin bolus quantities |
| US8333714B2 (en) | 2006-09-10 | 2012-12-18 | Abbott Diabetes Care Inc. | Method and system for providing an integrated analyte sensor insertion device and data processing unit |
| US7731657B2 (en) * | 2005-08-30 | 2010-06-08 | Abbott Diabetes Care Inc. | Analyte sensor introducer and methods of use |
| US7883464B2 (en) | 2005-09-30 | 2011-02-08 | Abbott Diabetes Care Inc. | Integrated transmitter unit and sensor introducer mechanism and methods of use |
| US9259175B2 (en) | 2006-10-23 | 2016-02-16 | Abbott Diabetes Care, Inc. | Flexible patch for fluid delivery and monitoring body analytes |
| US10226207B2 (en) | 2004-12-29 | 2019-03-12 | Abbott Diabetes Care Inc. | Sensor inserter having introducer |
| US8512243B2 (en) | 2005-09-30 | 2013-08-20 | Abbott Diabetes Care Inc. | Integrated introducer and transmitter assembly and methods of use |
| US9572534B2 (en) | 2010-06-29 | 2017-02-21 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
| US9636450B2 (en) * | 2007-02-19 | 2017-05-02 | Udo Hoss | Pump system modular components for delivering medication and analyte sensing at seperate insertion sites |
| US8029441B2 (en) | 2006-02-28 | 2011-10-04 | Abbott Diabetes Care Inc. | Analyte sensor transmitter unit configuration for a data monitoring and management system |
| US7697967B2 (en) | 2005-12-28 | 2010-04-13 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
| US20090105569A1 (en) | 2006-04-28 | 2009-04-23 | Abbott Diabetes Care, Inc. | Introducer Assembly and Methods of Use |
| US9398882B2 (en) | 2005-09-30 | 2016-07-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor and data processing device |
| US9788771B2 (en) | 2006-10-23 | 2017-10-17 | Abbott Diabetes Care Inc. | Variable speed sensor insertion devices and methods of use |
| ITBO20050002A1 (en) * | 2005-01-04 | 2006-07-05 | Giacomo Vespasiani | METHOD AND SYSTEM FOR INTERACTIVE MANAGEMENT OF DATA CONCERNING AN INSULIN THERAPY IN SELF-CONTROL FOR A DIABETIC PATIENT |
| US7547281B2 (en) * | 2005-02-01 | 2009-06-16 | Medtronic Minimed, Inc. | Algorithm sensor augmented bolus estimator for semi-closed loop infusion system |
| US7545272B2 (en) | 2005-02-08 | 2009-06-09 | Therasense, Inc. | RF tag on test strips, test strip vials and boxes |
| US8956291B2 (en) | 2005-02-22 | 2015-02-17 | Admetsys Corporation | Balanced physiological monitoring and treatment system |
| US20090076360A1 (en) | 2007-09-13 | 2009-03-19 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US8133178B2 (en) | 2006-02-22 | 2012-03-13 | Dexcom, Inc. | Analyte sensor |
| CN101180093B (en) | 2005-03-21 | 2012-07-18 | 雅培糖尿病护理公司 | Method and system for providing integrated medication infusion and analyte monitoring system |
| JP2008537903A (en) | 2005-04-13 | 2008-10-02 | グルコライト・コーポレーシヨン | Data processing and calibration method for blood glucose monitor based on OCT |
| US20080254661A1 (en) * | 2005-04-29 | 2008-10-16 | Byrne Norman R | Center Connect Single-Sided Junction Block |
| US8112240B2 (en) | 2005-04-29 | 2012-02-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing leak detection in data monitoring and management systems |
| US7383072B2 (en) * | 2005-05-09 | 2008-06-03 | P. J. Edmonson Ltd | Sweat sensor system and method of characterizing the compositional analysis of sweat fluid |
| CA2612714C (en) * | 2005-05-13 | 2013-09-24 | Trustees Of Boston University | Fully automated control system for type 1 diabetes |
| US7768408B2 (en) | 2005-05-17 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing data management in data monitoring system |
| US7620437B2 (en) | 2005-06-03 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and apparatus for providing rechargeable power in data monitoring and management systems |
| EP1728468A1 (en) * | 2005-06-04 | 2006-12-06 | Roche Diagnostics GmbH | Evaluation of blood glucose concentration values for adaptation of insulin dosage |
| US20060276771A1 (en) * | 2005-06-06 | 2006-12-07 | Galley Paul J | System and method providing for user intervention in a diabetes control arrangement |
| US8652037B2 (en) * | 2005-06-08 | 2014-02-18 | AgaMatrix, LLC | Data collection system and interface |
| US7670288B2 (en) * | 2005-06-08 | 2010-03-02 | Sher Philip M | Fluctuating blood glucose notification threshold profiles and methods of use |
| US20080314395A1 (en) | 2005-08-31 | 2008-12-25 | Theuniversity Of Virginia Patent Foundation | Accuracy of Continuous Glucose Sensors |
| EP1921978B1 (en) * | 2005-09-09 | 2012-08-01 | F. Hoffmann-La Roche AG | Device and program for diabetes care |
| US7756561B2 (en) | 2005-09-30 | 2010-07-13 | Abbott Diabetes Care Inc. | Method and apparatus for providing rechargeable power in data monitoring and management systems |
| US8880138B2 (en) | 2005-09-30 | 2014-11-04 | Abbott Diabetes Care Inc. | Device for channeling fluid and methods of use |
| US9521968B2 (en) | 2005-09-30 | 2016-12-20 | Abbott Diabetes Care Inc. | Analyte sensor retention mechanism and methods of use |
| NL1030272C1 (en) * | 2005-10-26 | 2007-04-27 | Variak | Device for automatically regulating the concentration of glucose in the blood of a diabetes patient. |
| WO2007051139A2 (en) * | 2005-10-27 | 2007-05-03 | Insulet Corporation | Diabetes management systems and methods |
| US7583190B2 (en) | 2005-10-31 | 2009-09-01 | Abbott Diabetes Care Inc. | Method and apparatus for providing data communication in data monitoring and management systems |
| US7766829B2 (en) * | 2005-11-04 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
| EP1955240B8 (en) * | 2005-11-08 | 2016-03-30 | Bigfoot Biomedical, Inc. | Method for manual and autonomous control of an infusion pump |
| US7941200B2 (en) * | 2005-12-08 | 2011-05-10 | Roche Diagnostics Operations, Inc. | System and method for determining drug administration information |
| DE102005059444A1 (en) * | 2005-12-09 | 2007-06-14 | Ahlers, Horst, Dr. | Medication e.g. insulin, optimal dosage determining method for diabetes, involves comparing characteristics vectors with search algorithm from object recognizing theory with new characteristics vectors for largest possible correlation |
| US11298058B2 (en) | 2005-12-28 | 2022-04-12 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
| US8114268B2 (en) * | 2005-12-30 | 2012-02-14 | Medtronic Minimed, Inc. | Method and system for remedying sensor malfunctions detected by electrochemical impedance spectroscopy |
| US8114269B2 (en) | 2005-12-30 | 2012-02-14 | Medtronic Minimed, Inc. | System and method for determining the point of hydration and proper time to apply potential to a glucose sensor |
| US7985330B2 (en) * | 2005-12-30 | 2011-07-26 | Medtronic Minimed, Inc. | Method and system for detecting age, hydration, and functional states of sensors using electrochemical impedance spectroscopy |
| WO2007081853A2 (en) * | 2006-01-05 | 2007-07-19 | University Of Virginia Patent Foundation | Method, system and computer program product for evaluation of blood glucose variability in diabetes from self-monitoring data |
| US9757061B2 (en) | 2006-01-17 | 2017-09-12 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
| US7736310B2 (en) | 2006-01-30 | 2010-06-15 | Abbott Diabetes Care Inc. | On-body medical device securement |
| US8344966B2 (en) | 2006-01-31 | 2013-01-01 | Abbott Diabetes Care Inc. | Method and system for providing a fault tolerant display unit in an electronic device |
| US7981034B2 (en) | 2006-02-28 | 2011-07-19 | Abbott Diabetes Care Inc. | Smart messages and alerts for an infusion delivery and management system |
| US7885698B2 (en) | 2006-02-28 | 2011-02-08 | Abbott Diabetes Care Inc. | Method and system for providing continuous calibration of implantable analyte sensors |
| US7826879B2 (en) | 2006-02-28 | 2010-11-02 | Abbott Diabetes Care Inc. | Analyte sensors and methods of use |
| EP1839692B1 (en) * | 2006-03-30 | 2007-11-28 | Roche Diagnostics GmbH | Infusion system comprising an infusion unit and a remote control unit |
| US8140312B2 (en) | 2007-05-14 | 2012-03-20 | Abbott Diabetes Care Inc. | Method and system for determining analyte levels |
| US7653425B2 (en) | 2006-08-09 | 2010-01-26 | Abbott Diabetes Care Inc. | Method and system for providing calibration of an analyte sensor in an analyte monitoring system |
| US8226891B2 (en) | 2006-03-31 | 2012-07-24 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods therefor |
| US8374668B1 (en) | 2007-10-23 | 2013-02-12 | Abbott Diabetes Care Inc. | Analyte sensor with lag compensation |
| US20130184547A1 (en) * | 2011-12-30 | 2013-07-18 | Abbott Diabetes Care Inc. | Method and Apparatus for Determining Medication Dose Information |
| US7630748B2 (en) | 2006-10-25 | 2009-12-08 | Abbott Diabetes Care Inc. | Method and system for providing analyte monitoring |
| US9675290B2 (en) | 2012-10-30 | 2017-06-13 | Abbott Diabetes Care Inc. | Sensitivity calibration of in vivo sensors used to measure analyte concentration |
| US9392969B2 (en) | 2008-08-31 | 2016-07-19 | Abbott Diabetes Care Inc. | Closed loop control and signal attenuation detection |
| US8224415B2 (en) | 2009-01-29 | 2012-07-17 | Abbott Diabetes Care Inc. | Method and device for providing offset model based calibration for analyte sensor |
| US7620438B2 (en) | 2006-03-31 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for powering an electronic device |
| US7618369B2 (en) | 2006-10-02 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for dynamically updating calibration parameters for an analyte sensor |
| US8346335B2 (en) | 2008-03-28 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte sensor calibration management |
| US8473022B2 (en) | 2008-01-31 | 2013-06-25 | Abbott Diabetes Care Inc. | Analyte sensor with time lag compensation |
| US8219173B2 (en) | 2008-09-30 | 2012-07-10 | Abbott Diabetes Care Inc. | Optimizing analyte sensor calibration |
| JP5050401B2 (en) * | 2006-05-02 | 2012-10-17 | セイコーエプソン株式会社 | Drug intake support system |
| US20070276197A1 (en) * | 2006-05-24 | 2007-11-29 | Lifescan, Inc. | Systems and methods for providing individualized disease management |
| JP2007312922A (en) * | 2006-05-24 | 2007-12-06 | Sysmex Corp | System for predicting biological response and program for the same |
| WO2007143225A2 (en) | 2006-06-07 | 2007-12-13 | Abbott Diabetes Care, Inc. | Analyte monitoring system and method |
| EP2046413A4 (en) * | 2006-07-21 | 2015-03-25 | Univ Colorado | Medical systems and methods of use |
| US8114023B2 (en) | 2006-07-28 | 2012-02-14 | Legacy Emanuel Hospital & Health Center | Analyte sensing and response system |
| US20110054391A1 (en) * | 2006-07-28 | 2011-03-03 | Ward W Kenneth | Analyte sensing and response system |
| US8932216B2 (en) * | 2006-08-07 | 2015-01-13 | Abbott Diabetes Care Inc. | Method and system for providing data management in integrated analyte monitoring and infusion system |
| US8206296B2 (en) | 2006-08-07 | 2012-06-26 | Abbott Diabetes Care Inc. | Method and system for providing integrated analyte monitoring and infusion system therapy management |
| JP5266221B2 (en) * | 2006-08-08 | 2013-08-21 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | Method and apparatus for monitoring physiological parameters |
| US9056165B2 (en) * | 2006-09-06 | 2015-06-16 | Medtronic Minimed, Inc. | Intelligent therapy recommendation algorithm and method of using the same |
| US8805759B1 (en) | 2006-09-06 | 2014-08-12 | Healthcare Interactive, Inc. | System and method for psychographic profiling of targeted populations of individuals |
| US8275438B2 (en) * | 2006-10-04 | 2012-09-25 | Dexcom, Inc. | Analyte sensor |
| US8298142B2 (en) * | 2006-10-04 | 2012-10-30 | Dexcom, Inc. | Analyte sensor |
| US8447376B2 (en) * | 2006-10-04 | 2013-05-21 | Dexcom, Inc. | Analyte sensor |
| US8562528B2 (en) * | 2006-10-04 | 2013-10-22 | Dexcom, Inc. | Analyte sensor |
| US8449464B2 (en) * | 2006-10-04 | 2013-05-28 | Dexcom, Inc. | Analyte sensor |
| US8478377B2 (en) | 2006-10-04 | 2013-07-02 | Dexcom, Inc. | Analyte sensor |
| JP2010507176A (en) | 2006-10-16 | 2010-03-04 | ホスピラ・インコーポレイテツド | System and method for comparing and utilizing dynamic information and configuration information from multiple device management systems |
| BRPI0718119A2 (en) | 2006-10-26 | 2014-07-08 | Abbott Diabetes Care Inc | COMPUTER METHODS, SYSTEMS, AND PROGRAMS FOR REAL-TIME DETECTION OF THE ANALYTIC SENSOR SENSITIVITY DECLINE |
| US8439837B2 (en) * | 2006-10-31 | 2013-05-14 | Lifescan, Inc. | Systems and methods for detecting hypoglycemic events having a reduced incidence of false alarms |
| US20080119710A1 (en) * | 2006-10-31 | 2008-05-22 | Abbott Diabetes Care, Inc. | Medical devices and methods of using the same |
| US8579853B2 (en) | 2006-10-31 | 2013-11-12 | Abbott Diabetes Care Inc. | Infusion devices and methods |
| US8204729B2 (en) * | 2006-11-01 | 2012-06-19 | Philip Michael Sher | Device for predicting and managing blood glucose by analyzing the effect of, and controlling, pharmacodynamic insulin equivalents |
| US20080306353A1 (en) * | 2006-11-03 | 2008-12-11 | Douglas Joel S | Calculation device for metabolic control of critically ill and/or diabetic patients |
| US20080139910A1 (en) * | 2006-12-06 | 2008-06-12 | Metronic Minimed, Inc. | Analyte sensor and method of using the same |
| US20080154513A1 (en) * | 2006-12-21 | 2008-06-26 | University Of Virginia Patent Foundation | Systems, Methods and Computer Program Codes for Recognition of Patterns of Hyperglycemia and Hypoglycemia, Increased Glucose Variability, and Ineffective Self-Monitoring in Diabetes |
| US20080214919A1 (en) * | 2006-12-26 | 2008-09-04 | Lifescan, Inc. | System and method for implementation of glycemic control protocols |
| US7946985B2 (en) * | 2006-12-29 | 2011-05-24 | Medtronic Minimed, Inc. | Method and system for providing sensor redundancy |
| US7734323B2 (en) * | 2007-01-24 | 2010-06-08 | Smiths Medical Asd, Inc. | Correction factor testing using frequent blood glucose input |
| US10154804B2 (en) | 2007-01-31 | 2018-12-18 | Medtronic Minimed, Inc. | Model predictive method and system for controlling and supervising insulin infusion |
| EP2989975B1 (en) * | 2007-02-06 | 2018-06-13 | Medtronic MiniMed, Inc. | Optical systems and methods for rationmetric measurement of blood glucose concentration |
| US8121857B2 (en) | 2007-02-15 | 2012-02-21 | Abbott Diabetes Care Inc. | Device and method for automatic data acquisition and/or detection |
| US20080199894A1 (en) | 2007-02-15 | 2008-08-21 | Abbott Diabetes Care, Inc. | Device and method for automatic data acquisition and/or detection |
| US20080220403A1 (en) * | 2007-02-16 | 2008-09-11 | Ohio University | System and method for managing diabetes |
| US8732188B2 (en) | 2007-02-18 | 2014-05-20 | Abbott Diabetes Care Inc. | Method and system for providing contextual based medication dosage determination |
| US8930203B2 (en) | 2007-02-18 | 2015-01-06 | Abbott Diabetes Care Inc. | Multi-function analyte test device and methods therefor |
| US20080206799A1 (en) * | 2007-02-27 | 2008-08-28 | Michael Blomquist | Carbohydrate ratio testing using frequent blood glucose input |
| US8123686B2 (en) | 2007-03-01 | 2012-02-28 | Abbott Diabetes Care Inc. | Method and apparatus for providing rolling data in communication systems |
| US20080228056A1 (en) | 2007-03-13 | 2008-09-18 | Michael Blomquist | Basal rate testing using frequent blood glucose input |
| CN104069567A (en) * | 2007-03-19 | 2014-10-01 | 茵苏莱恩医药有限公司 | Drug delivery device |
| US8622991B2 (en) * | 2007-03-19 | 2014-01-07 | Insuline Medical Ltd. | Method and device for drug delivery |
| EP2136863A2 (en) * | 2007-03-19 | 2009-12-30 | Insuline Medical Ltd. | Device for drug delivery and associated connections thereto |
| US9220837B2 (en) * | 2007-03-19 | 2015-12-29 | Insuline Medical Ltd. | Method and device for drug delivery |
| US20100292557A1 (en) * | 2007-03-19 | 2010-11-18 | Benny Pesach | Method and device for substance measurement |
| US8758245B2 (en) * | 2007-03-20 | 2014-06-24 | Lifescan, Inc. | Systems and methods for pattern recognition in diabetes management |
| US20080235053A1 (en) * | 2007-03-20 | 2008-09-25 | Pinaki Ray | Communication medium for diabetes management |
| US20080234943A1 (en) * | 2007-03-20 | 2008-09-25 | Pinaki Ray | Computer program for diabetes management |
| US10111608B2 (en) | 2007-04-14 | 2018-10-30 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
| WO2008130895A2 (en) | 2007-04-14 | 2008-10-30 | Abbott Diabetes Care, Inc. | Method and apparatus for providing dynamic multi-stage signal amplification in a medical device |
| US9615780B2 (en) * | 2007-04-14 | 2017-04-11 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
| CA2683962C (en) | 2007-04-14 | 2017-06-06 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
| CA2683930A1 (en) | 2007-04-14 | 2008-10-23 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
| US9204827B2 (en) | 2007-04-14 | 2015-12-08 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
| EP2146626A1 (en) * | 2007-04-20 | 2010-01-27 | Veridex, LLC | A method for determining insulin sensitivity and glucose absorption |
| US20080269714A1 (en) | 2007-04-25 | 2008-10-30 | Medtronic Minimed, Inc. | Closed loop/semi-closed loop therapy modification system |
| US20080269723A1 (en) * | 2007-04-25 | 2008-10-30 | Medtronic Minimed, Inc. | Closed loop/semi-closed loop therapy modification system |
| US8461985B2 (en) | 2007-05-08 | 2013-06-11 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
| US8456301B2 (en) | 2007-05-08 | 2013-06-04 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
| US7928850B2 (en) | 2007-05-08 | 2011-04-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
| US8665091B2 (en) | 2007-05-08 | 2014-03-04 | Abbott Diabetes Care Inc. | Method and device for determining elapsed sensor life |
| CA2686065A1 (en) | 2007-05-10 | 2008-11-20 | Glumetrics, Inc. | Equilibrium non-consuming fluorescence sensor for real time intravascular glucose measurement |
| US8239166B2 (en) | 2007-05-14 | 2012-08-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| US8444560B2 (en) | 2007-05-14 | 2013-05-21 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| US8103471B2 (en) | 2007-05-14 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| US8600681B2 (en) | 2007-05-14 | 2013-12-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| US8560038B2 (en) | 2007-05-14 | 2013-10-15 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| US8260558B2 (en) | 2007-05-14 | 2012-09-04 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| US9125548B2 (en) | 2007-05-14 | 2015-09-08 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| US10002233B2 (en) | 2007-05-14 | 2018-06-19 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| US7996158B2 (en) | 2007-05-14 | 2011-08-09 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| US8417311B2 (en) * | 2008-09-12 | 2013-04-09 | Optiscan Biomedical Corporation | Fluid component analysis system and method for glucose monitoring and control |
| US7751907B2 (en) | 2007-05-24 | 2010-07-06 | Smiths Medical Asd, Inc. | Expert system for insulin pump therapy |
| US8221345B2 (en) | 2007-05-30 | 2012-07-17 | Smiths Medical Asd, Inc. | Insulin pump based expert system |
| WO2008150917A1 (en) * | 2007-05-31 | 2008-12-11 | Abbott Diabetes Care, Inc. | Insertion devices and methods |
| US20080306434A1 (en) | 2007-06-08 | 2008-12-11 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
| WO2009013637A2 (en) * | 2007-06-20 | 2009-01-29 | Medingo Headquarters | Method and device for assessing carbohydrate-to-insulin ratio |
| ES2693432T3 (en) * | 2007-06-21 | 2018-12-11 | F. Hoffmann-La Roche Ag | Method and device to prevent hypoglycemia |
| AU2008265542B2 (en) | 2007-06-21 | 2014-07-24 | Abbott Diabetes Care Inc. | Health monitor |
| EP2171031B1 (en) | 2007-06-21 | 2018-12-05 | Abbott Diabetes Care Inc. | Health management devices and methods |
| CN101689224B (en) * | 2007-06-27 | 2015-06-17 | 霍夫曼-拉罗奇有限公司 | System for developing patient specific therapies based on dynamic modeling of patient physiology and method thereof |
| EP2191405B1 (en) | 2007-06-27 | 2019-05-01 | Roche Diabetes Care GmbH | Medical diagnosis, therapy, and prognosis system for invoked events and method thereof |
| US8641618B2 (en) | 2007-06-27 | 2014-02-04 | Abbott Diabetes Care Inc. | Method and structure for securing a monitoring device element |
| US8160900B2 (en) | 2007-06-29 | 2012-04-17 | Abbott Diabetes Care Inc. | Analyte monitoring and management device and method to analyze the frequency of user interaction with the device |
| US20090036753A1 (en) * | 2007-07-31 | 2009-02-05 | King Allen B | Continuous glucose monitoring-directed adjustments in basal insulin rate and insulin bolus dosing formulas |
| US20090036760A1 (en) * | 2007-07-31 | 2009-02-05 | Abbott Diabetes Care, Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| US8834366B2 (en) * | 2007-07-31 | 2014-09-16 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor calibration |
| US20090063402A1 (en) * | 2007-08-31 | 2009-03-05 | Abbott Diabetes Care, Inc. | Method and System for Providing Medication Level Determination |
| US7998069B2 (en) * | 2007-09-11 | 2011-08-16 | Roche Diagnostics Operations, Inc. | Mask algorithms for health management systems |
| WO2009049252A1 (en) | 2007-10-10 | 2009-04-16 | Optiscan Biomedical Corporation | Fluid component analysis system and method for glucose monitoring and control |
| US7731659B2 (en) * | 2007-10-18 | 2010-06-08 | Lifescan Scotland Limited | Method for predicting a user's future glycemic state |
| US7695434B2 (en) * | 2007-10-19 | 2010-04-13 | Lifescan Scotland, Ltd. | Medical device for predicting a user's future glycemic state |
| US8409093B2 (en) | 2007-10-23 | 2013-04-02 | Abbott Diabetes Care Inc. | Assessing measures of glycemic variability |
| US8216138B1 (en) | 2007-10-23 | 2012-07-10 | Abbott Diabetes Care Inc. | Correlation of alternative site blood and interstitial fluid glucose concentrations to venous glucose concentration |
| US8377031B2 (en) | 2007-10-23 | 2013-02-19 | Abbott Diabetes Care Inc. | Closed loop control system with safety parameters and methods |
| US8417312B2 (en) | 2007-10-25 | 2013-04-09 | Dexcom, Inc. | Systems and methods for processing sensor data |
| IL194966A0 (en) * | 2007-10-31 | 2009-08-03 | Animas Corp | User interface for insulin infusion device |
| WO2009060433A1 (en) * | 2007-11-09 | 2009-05-14 | Medingo Ltd. | Assessing residual insulin time |
| JP5631215B2 (en) | 2007-11-21 | 2014-11-26 | メドトロニック ミニメド インコーポレイテッド | Blood sugar management maintenance system |
| US8019721B2 (en) * | 2007-12-07 | 2011-09-13 | Roche Diagnostics Operations, Inc. | Method and system for enhanced data transfer |
| US7979136B2 (en) * | 2007-12-07 | 2011-07-12 | Roche Diagnostics Operation, Inc | Method and system for multi-device communication |
| US8103241B2 (en) * | 2007-12-07 | 2012-01-24 | Roche Diagnostics Operations, Inc. | Method and system for wireless device communication |
| US8402151B2 (en) | 2007-12-07 | 2013-03-19 | Roche Diagnostics Operations, Inc. | Dynamic communication stack |
| US20090150877A1 (en) * | 2007-12-07 | 2009-06-11 | Roche Diagnostics Operations, Inc. | Data driven communication protocol grammar |
| US8078592B2 (en) * | 2007-12-07 | 2011-12-13 | Roche Diagnostics Operations, Inc. | System and method for database integrity checking |
| US20100262434A1 (en) * | 2007-12-13 | 2010-10-14 | Shaya Steven A | Method and apparatus to calculate diabetic sensitivity factors affecting blood glucose |
| US9839395B2 (en) | 2007-12-17 | 2017-12-12 | Dexcom, Inc. | Systems and methods for processing sensor data |
| US8409133B2 (en) | 2007-12-18 | 2013-04-02 | Insuline Medical Ltd. | Drug delivery device with sensor for closed-loop operation |
| US9026370B2 (en) | 2007-12-18 | 2015-05-05 | Hospira, Inc. | User interface improvements for medical devices |
| US20090164190A1 (en) * | 2007-12-19 | 2009-06-25 | Abbott Diabetes Care, Inc. | Physiological condition simulation device and method |
| US20090164239A1 (en) * | 2007-12-19 | 2009-06-25 | Abbott Diabetes Care, Inc. | Dynamic Display Of Glucose Information |
| US20090177147A1 (en) * | 2008-01-07 | 2009-07-09 | Michael Blomquist | Insulin pump with insulin therapy coaching |
| US20090177142A1 (en) | 2008-01-09 | 2009-07-09 | Smiths Medical Md, Inc | Insulin pump with add-on modules |
| US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
| US20100138453A1 (en) * | 2008-02-12 | 2010-06-03 | Alferness Clifton A | System and method for generating a personalized diabetes management tool for diabetes mellitus |
| US20100198020A1 (en) * | 2008-02-12 | 2010-08-05 | Alferness Clifton A | System And Method For Computer-Implemented Method For Actively Managing Increased Insulin Resistance In Type 2 Diabetes Mellitus |
| US20110077930A1 (en) * | 2008-02-12 | 2011-03-31 | Alferness Clifton A | Computer-implemented method for providing a personalized tool for estimating 1,5-anhydroglucitol |
| US20100145670A1 (en) * | 2008-02-12 | 2010-06-10 | Alferness Clifton A | System and method for managing type 2 diabetes mellitus through a personal predictive management tool |
| US20100145725A1 (en) * | 2008-02-12 | 2010-06-10 | Alferness Clifton A | System and method for managing type 1 diabetes mellitus through a personal predictive management tool |
| US20100138203A1 (en) * | 2008-02-12 | 2010-06-03 | Alferness Clifton A | System and method for actively managing type 2 diabetes mellitus on a personalized basis |
| US20100145174A1 (en) * | 2008-02-12 | 2010-06-10 | Alferness Clifton A | System And Method For Providing A Personalized Tool For Estimating Glycated Hemoglobin |
| US20100137786A1 (en) * | 2008-02-12 | 2010-06-03 | Alferness Clifton A | System and method for actively managing type 1 diabetes mellitus on a personalized basis |
| US20100198021A1 (en) * | 2008-02-12 | 2010-08-05 | Alferness Clifton A | Computer-implemented method for providing a tunable personalized tool for estimating glycated hemoglobin |
| US20100145173A1 (en) * | 2008-02-12 | 2010-06-10 | Alferness Clifton A | System and method for creating a personalized tool predicting a time course of blood glucose affect in diabetes mellitus |
| WO2009105337A2 (en) * | 2008-02-20 | 2009-08-27 | Dexcom, Inc. | Continuous medicament sensor system for in vivo use |
| EP2252196A4 (en) | 2008-02-21 | 2013-05-15 | Dexcom Inc | Systems and methods for processing, transmitting and displaying sensor data |
| US8571617B2 (en) | 2008-03-04 | 2013-10-29 | Glt Acquisition Corp. | Flowometry in optical coherence tomography for analyte level estimation |
| US20090240127A1 (en) * | 2008-03-20 | 2009-09-24 | Lifescan, Inc. | Methods of determining pre or post meal time slots or intervals in diabetes management |
| US8396528B2 (en) | 2008-03-25 | 2013-03-12 | Dexcom, Inc. | Analyte sensor |
| US20090242399A1 (en) * | 2008-03-25 | 2009-10-01 | Dexcom, Inc. | Analyte sensor |
| US10624577B2 (en) | 2008-04-04 | 2020-04-21 | Hygieia, Inc. | Systems, devices, and methods for alleviating glucotoxicity and restoring pancreatic beta-cell function in advanced diabetes mellitus |
| US8600682B2 (en) * | 2008-04-04 | 2013-12-03 | Hygieia, Inc. | Apparatus for optimizing a patient's insulin dosage regimen |
| US9220456B2 (en) | 2008-04-04 | 2015-12-29 | Hygieia, Inc. | Systems, methods and devices for achieving glycemic balance |
| WO2009129186A2 (en) | 2008-04-17 | 2009-10-22 | Glumetrics, Inc. | Sensor for percutaneous intravascular deployment without an indwelling cannula |
| EP2297662B1 (en) * | 2008-04-29 | 2019-08-07 | Roche Diabetes Care GmbH | Methods and apparatuses for selecting a bolus delivery pattern in a drug delivery device |
| US20100256047A1 (en) * | 2009-04-03 | 2010-10-07 | Lifescan, Inc. | Analyte Measurement and Management Device and Associated Methods |
| US20090281519A1 (en) * | 2008-05-12 | 2009-11-12 | Rao R Harsha | Automated system and method for diabetes control |
| US8924159B2 (en) | 2008-05-30 | 2014-12-30 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
| US7826382B2 (en) | 2008-05-30 | 2010-11-02 | Abbott Diabetes Care Inc. | Close proximity communication device and methods |
| US8591410B2 (en) | 2008-05-30 | 2013-11-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
| US8876755B2 (en) | 2008-07-14 | 2014-11-04 | Abbott Diabetes Care Inc. | Closed loop control system interface and methods |
| CN102548467A (en) * | 2008-07-18 | 2012-07-04 | 生命扫描有限公司 | Analyte measurement and management device and associated methods |
| US20110137208A1 (en) * | 2008-07-24 | 2011-06-09 | Admetsys Corporation | Device and method for automatically sampling and measuring blood analytes |
| EP2149957B1 (en) * | 2008-07-30 | 2017-06-14 | Harman Becker Automotive Systems GmbH | Priority based power distribution arrangement |
| US8700114B2 (en) | 2008-07-31 | 2014-04-15 | Medtronic Minmed, Inc. | Analyte sensor apparatuses comprising multiple implantable sensor elements and methods for making and using them |
| US20110160555A1 (en) * | 2008-07-31 | 2011-06-30 | Jacques Reifman | Universal Models for Predicting Glucose Concentration in Humans |
| US8762306B2 (en) * | 2008-08-14 | 2014-06-24 | The University Of Toledo | Neural network for glucose therapy recommendation |
| US7959598B2 (en) | 2008-08-20 | 2011-06-14 | Asante Solutions, Inc. | Infusion pump systems and methods |
| US9943644B2 (en) * | 2008-08-31 | 2018-04-17 | Abbott Diabetes Care Inc. | Closed loop control with reference measurement and methods thereof |
| US20100057040A1 (en) * | 2008-08-31 | 2010-03-04 | Abbott Diabetes Care, Inc. | Robust Closed Loop Control And Methods |
| US8622988B2 (en) * | 2008-08-31 | 2014-01-07 | Abbott Diabetes Care Inc. | Variable rate closed loop control and methods |
| US8734422B2 (en) * | 2008-08-31 | 2014-05-27 | Abbott Diabetes Care Inc. | Closed loop control with improved alarm functions |
| US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
| US8650937B2 (en) | 2008-09-19 | 2014-02-18 | Tandem Diabetes Care, Inc. | Solute concentration measurement device and related methods |
| EP2326944B1 (en) | 2008-09-19 | 2020-08-19 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
| US8986208B2 (en) | 2008-09-30 | 2015-03-24 | Abbott Diabetes Care Inc. | Analyte sensor sensitivity attenuation mitigation |
| US8983568B2 (en) * | 2008-09-30 | 2015-03-17 | Abbott Diabetes Care Inc. | Analyte sensors comprising leveling agents |
| JP5323853B2 (en) * | 2008-10-08 | 2013-10-23 | 旭化成ファーマ株式会社 | Blood sample analysis method, blood sample analysis device, and program |
| US8287487B2 (en) * | 2008-10-15 | 2012-10-16 | Asante Solutions, Inc. | Infusion pump system and methods |
| RU2532893C2 (en) | 2008-11-07 | 2014-11-10 | Инсьюлин Медикал Лтд. | Drug delivery device and method |
| US9326707B2 (en) | 2008-11-10 | 2016-05-03 | Abbott Diabetes Care Inc. | Alarm characterization for analyte monitoring devices and systems |
| WO2010056718A2 (en) | 2008-11-11 | 2010-05-20 | Hygieia, Inc. | Apparatus and system for diabetes management |
| GB2466183A (en) * | 2008-12-09 | 2010-06-16 | Cambridge Entpr Ltd | Closed loop diabetes management system |
| US9117015B2 (en) | 2008-12-23 | 2015-08-25 | Roche Diagnostics Operations, Inc. | Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device |
| KR101285520B1 (en) | 2008-12-23 | 2013-07-17 | 에프. 호프만-라 로슈 아게 | Structured testing method for diagnostic or therapy support of a patient with a chronic disease and devices thereof |
| US10437962B2 (en) | 2008-12-23 | 2019-10-08 | Roche Diabetes Care Inc | Status reporting of a structured collection procedure |
| US8849458B2 (en) * | 2008-12-23 | 2014-09-30 | Roche Diagnostics Operations, Inc. | Collection device with selective display of test results, method and computer program product thereof |
| US20120011125A1 (en) | 2008-12-23 | 2012-01-12 | Roche Diagnostics Operations, Inc. | Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device |
| US10456036B2 (en) * | 2008-12-23 | 2019-10-29 | Roche Diabetes Care, Inc. | Structured tailoring |
| US9918635B2 (en) | 2008-12-23 | 2018-03-20 | Roche Diabetes Care, Inc. | Systems and methods for optimizing insulin dosage |
| EP3677293A1 (en) | 2009-01-12 | 2020-07-08 | Becton, Dickinson and Company | In-dwelling rigid catheter with flexible features |
| US9375529B2 (en) * | 2009-09-02 | 2016-06-28 | Becton, Dickinson And Company | Extended use medical device |
| US8103456B2 (en) | 2009-01-29 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
| US8560082B2 (en) | 2009-01-30 | 2013-10-15 | Abbott Diabetes Care Inc. | Computerized determination of insulin pump therapy parameters using real time and retrospective data processing |
| US9402544B2 (en) | 2009-02-03 | 2016-08-02 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
| CA2750049C (en) | 2009-02-04 | 2021-02-23 | Sanofi-Aventis Deutschland Gmbh | Medical device and method for providing information for glycemic control |
| WO2010091129A1 (en) * | 2009-02-04 | 2010-08-12 | Abbott Diabetes Care Inc. | Multi-function analyte test device and methods therefor |
| US10478100B2 (en) | 2009-02-04 | 2019-11-19 | Sanofi-Aventis Deutschland Gmbh | Medical system and method for providing information for glycemic control |
| JP5783912B2 (en) | 2009-02-04 | 2015-09-24 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Medical system and method for providing glycemic control based on glycemic response information |
| AU2010210155B2 (en) | 2009-02-04 | 2015-04-09 | Sanofi-Aventis Deutschland Gmbh | Medical device and method for glycemic control |
| KR20120047841A (en) * | 2009-02-26 | 2012-05-14 | 몰 리서치 어플리케이션스 엘티디 | Method and system for automatic monitoring of diabetes related treatment |
| US10136816B2 (en) | 2009-08-31 | 2018-11-27 | Abbott Diabetes Care Inc. | Medical devices and methods |
| LT3912551T (en) * | 2009-02-26 | 2023-12-11 | Abbott Diabetes Care, Inc. | Method of calibrating an analyte sensor |
| EP2410910A4 (en) | 2009-03-27 | 2014-10-15 | Dexcom Inc | Methods and systems for promoting glucose management |
| US7896498B2 (en) * | 2009-03-30 | 2011-03-01 | Ottawa Hospital Research Institute | Apparatus and method for optical measurements |
| WO2010121084A1 (en) | 2009-04-15 | 2010-10-21 | Abbott Diabetes Care Inc. | Analyte monitoring system having an alert |
| EP2419015A4 (en) | 2009-04-16 | 2014-08-20 | Abbott Diabetes Care Inc | Analyte sensor calibration management |
| US8271106B2 (en) | 2009-04-17 | 2012-09-18 | Hospira, Inc. | System and method for configuring a rule set for medical event management and responses |
| US8467972B2 (en) | 2009-04-28 | 2013-06-18 | Abbott Diabetes Care Inc. | Closed loop blood glucose control algorithm analysis |
| WO2010127050A1 (en) | 2009-04-28 | 2010-11-04 | Abbott Diabetes Care Inc. | Error detection in critical repeating data in a wireless sensor system |
| US20100274515A1 (en) * | 2009-04-28 | 2010-10-28 | Abbott Diabetes Care Inc. | Dynamic Analyte Sensor Calibration Based On Sensor Stability Profile |
| US8368556B2 (en) | 2009-04-29 | 2013-02-05 | Abbott Diabetes Care Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
| EP2425209A4 (en) | 2009-04-29 | 2013-01-09 | Abbott Diabetes Care Inc | Method and system for providing real time analyte sensor calibration with retrospective backfill |
| US10420489B2 (en) * | 2009-05-29 | 2019-09-24 | University Of Virginia Patent Foundation | System coordinator and modular architecture for open-loop and closed-loop control of diabetes |
| WO2010138856A1 (en) | 2009-05-29 | 2010-12-02 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
| JP5546162B2 (en) * | 2009-06-02 | 2014-07-09 | 日機装株式会社 | Patient data management device |
| US20100332445A1 (en) * | 2009-06-30 | 2010-12-30 | Lifescan, Inc. | Analyte testing method and system |
| JP5654587B2 (en) * | 2009-06-30 | 2015-01-14 | ライフスキャン・インコーポレイテッドＬｉｆｅｓｃａｎ，Ｉｎｃ． | Analyte test method and apparatus for calculating basal insulin therapy |
| WO2011002791A2 (en) * | 2009-06-30 | 2011-01-06 | Lifescan Scotland Limited | Systems for diabetes management and methods |
| US20110012691A1 (en) * | 2009-07-15 | 2011-01-20 | Schoessow Michael J | 1:9 broadband transmission line transformer |
| US8939928B2 (en) | 2009-07-23 | 2015-01-27 | Becton, Dickinson And Company | Medical device having capacitive coupling communication and energy harvesting |
| EP4289355A3 (en) * | 2009-07-23 | 2024-02-28 | Abbott Diabetes Care Inc. | Continuous analyte measurement system |
| DK3173014T3 (en) | 2009-07-23 | 2021-09-13 | Abbott Diabetes Care Inc | Real-time control of data on physiological control of glucose levels |
| EP2724739B1 (en) | 2009-07-30 | 2015-07-01 | Tandem Diabetes Care, Inc. | Portable infusion pump system |
| WO2011014851A1 (en) | 2009-07-31 | 2011-02-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte monitoring system calibration accuracy |
| WO2011026148A1 (en) | 2009-08-31 | 2011-03-03 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods for managing power and noise |
| EP4147999A1 (en) | 2009-08-31 | 2023-03-15 | Abbott Diabetes Care, Inc. | Displays for a medical device |
| WO2011026147A1 (en) | 2009-08-31 | 2011-03-03 | Abbott Diabetes Care Inc. | Analyte signal processing device and methods |
| WO2011026149A1 (en) * | 2009-08-31 | 2011-03-03 | Abbott Diabetes Care Inc. | Mounting unit having a sensor and associated circuitry |
| CN102596307B (en) * | 2009-09-01 | 2015-09-09 | 弗吉尼亚大学专利基金会 | Utilize nominal open loop characteristic in diabetes, carry out system, the method and computer program product of insulin feed adjustment (AID) |
| US10092691B2 (en) | 2009-09-02 | 2018-10-09 | Becton, Dickinson And Company | Flexible and conformal patch pump |
| DK2482870T3 (en) | 2009-09-29 | 2018-04-16 | Admetsys Corp | Plant and method for distinguishing containers in the delivery of medicines |
| US9320461B2 (en) | 2009-09-29 | 2016-04-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
| JP5657678B2 (en) * | 2009-09-29 | 2015-01-21 | ライフスキャン・スコットランド・リミテッドＬｉｆｅＳｃａｎ Ｓｃｏｔｌａｎｄ， Ｌｔｄ． | Analyte testing method and device for diabetes management |
| DK2483824T3 (en) | 2009-09-30 | 2017-11-27 | Dreamed Diabetes Ltd | INSULIN CONTROL MONITORING MONITOR |
| WO2011041531A1 (en) | 2009-09-30 | 2011-04-07 | Abbott Diabetes Care Inc. | Interconnect for on-body analyte monitoring device |
| US20110077477A1 (en) * | 2009-09-30 | 2011-03-31 | Glumetrics, Inc. | Sensors with thromboresistant coating |
| WO2011053881A1 (en) | 2009-10-30 | 2011-05-05 | Abbott Diabetes Care Inc. | Method and apparatus for detecting false hypoglycemic conditions |
| US8467843B2 (en) | 2009-11-04 | 2013-06-18 | Glumetrics, Inc. | Optical sensor configuration for ratiometric correction of blood glucose measurement |
| US8882701B2 (en) | 2009-12-04 | 2014-11-11 | Smiths Medical Asd, Inc. | Advanced step therapy delivery for an ambulatory infusion pump and system |
| US8771251B2 (en) * | 2009-12-17 | 2014-07-08 | Hospira, Inc. | Systems and methods for managing and delivering patient therapy through electronic drug delivery systems |
| US8070723B2 (en) | 2009-12-31 | 2011-12-06 | Medtronic Minimed, Inc. | Activity guard |
| JP5750123B2 (en) * | 2010-02-11 | 2015-07-15 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | System, device and method for delivering a biological agent or drug to a subject |
| RU2553097C2 (en) * | 2010-02-25 | 2015-06-10 | Лайфскэн Скотлэнд Лимитед | Method of analyte testing and system for notification about tendencies of indices towards increase and decrease of glucose level in blood |
| WO2011112753A1 (en) | 2010-03-10 | 2011-09-15 | Abbott Diabetes Care Inc. | Systems, devices and methods for managing glucose levels |
| US8636711B2 (en) | 2010-06-14 | 2014-01-28 | Legacy Emanuel Hospital & Health Center | Stabilized glucagon solutions and uses therefor |
| US8532933B2 (en) | 2010-06-18 | 2013-09-10 | Roche Diagnostics Operations, Inc. | Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers |
| US10561785B2 (en) * | 2010-06-22 | 2020-02-18 | Medtronic Minimed, Inc. | Method and/or system for closed-loop control of glucose to a treatment range |
| US8635046B2 (en) | 2010-06-23 | 2014-01-21 | Abbott Diabetes Care Inc. | Method and system for evaluating analyte sensor response characteristics |
| US9215995B2 (en) | 2010-06-23 | 2015-12-22 | Medtronic Minimed, Inc. | Sensor systems having multiple probes and electrode arrays |
| US10092229B2 (en) | 2010-06-29 | 2018-10-09 | Abbott Diabetes Care Inc. | Calibration of analyte measurement system |
| US11064921B2 (en) | 2010-06-29 | 2021-07-20 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
| US8206340B2 (en) * | 2010-08-18 | 2012-06-26 | Thuban, Inc. | Integrated glucose monitor and insulin injection pen with automatic emergency notification |
| US8945094B2 (en) * | 2010-09-08 | 2015-02-03 | Honeywell International Inc. | Apparatus and method for medication delivery using single input-single output (SISO) model predictive control |
| WO2012048168A2 (en) | 2010-10-07 | 2012-04-12 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods |
| EP2633456B1 (en) | 2010-10-31 | 2019-09-04 | Trustees of Boston University | Blood glucose control system |
| US8814831B2 (en) | 2010-11-30 | 2014-08-26 | Becton, Dickinson And Company | Ballistic microneedle infusion device |
| US8795230B2 (en) | 2010-11-30 | 2014-08-05 | Becton, Dickinson And Company | Adjustable height needle infusion device |
| US9950109B2 (en) | 2010-11-30 | 2018-04-24 | Becton, Dickinson And Company | Slide-activated angled inserter and cantilevered ballistic insertion for intradermal drug infusion |
| US8628510B2 (en) | 2010-12-22 | 2014-01-14 | Medtronic Minimed, Inc. | Monitoring the operating health of a force sensor in a fluid infusion device |
| US20120173151A1 (en) | 2010-12-29 | 2012-07-05 | Roche Diagnostics Operations, Inc. | Methods of assessing diabetes treatment protocols based on protocol complexity levels and patient proficiency levels |
| FR2970418B1 (en) * | 2011-01-14 | 2013-01-11 | Hospices Civils Lyon | DEVICE FOR OPTIMIZING THE GLYCEMIA OF A PATIENT |
| US20120197622A1 (en) * | 2011-01-31 | 2012-08-02 | Fujitsu Limited | Monitoring Insulin Resistance |
| US9339639B2 (en) | 2011-02-22 | 2016-05-17 | Medtronic Minimed, Inc. | Sealing assembly for a fluid reservoir of a fluid infusion device |
| US11266823B2 (en) | 2011-02-22 | 2022-03-08 | Medtronic Minimed, Inc. | Retractable sealing assembly for a fluid reservoir of a fluid infusion device |
| US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
| CA3115682A1 (en) | 2011-02-28 | 2012-11-15 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
| CA2828077A1 (en) | 2011-03-18 | 2012-09-27 | Sanofi-Aventis Deutschland Gmbh | Calculating a medicament dose |
| ES2847578T3 (en) | 2011-04-15 | 2021-08-03 | Dexcom Inc | Advanced analyte sensor calibration and error detection |
| US9456755B2 (en) | 2011-04-29 | 2016-10-04 | Medtronic, Inc. | Method and device to monitor patients with kidney disease |
| US9561316B2 (en) | 2011-04-29 | 2017-02-07 | Medtronic, Inc. | Intersession monitoring for blood fluid removal therapy |
| US9848778B2 (en) | 2011-04-29 | 2017-12-26 | Medtronic, Inc. | Method and device to monitor patients with kidney disease |
| US9008744B2 (en) | 2011-05-06 | 2015-04-14 | Medtronic Minimed, Inc. | Method and apparatus for continuous analyte monitoring |
| US8795231B2 (en) | 2011-05-10 | 2014-08-05 | Medtronic Minimed, Inc. | Automated reservoir fill system |
| US8766803B2 (en) | 2011-05-13 | 2014-07-01 | Roche Diagnostics Operations, Inc. | Dynamic data collection |
| US8755938B2 (en) | 2011-05-13 | 2014-06-17 | Roche Diagnostics Operations, Inc. | Systems and methods for handling unacceptable values in structured collection protocols |
| US9240002B2 (en) | 2011-08-19 | 2016-01-19 | Hospira, Inc. | Systems and methods for a graphical interface including a graphical representation of medical data |
| JP6058673B2 (en) * | 2011-09-13 | 2017-01-11 | ノボ・ノルデイスク・エー／エス | An adaptive system for optimizing drug administration therapy over time |
| EP2760432B1 (en) | 2011-09-27 | 2019-03-20 | Medtronic Minimed, Inc. | Method for functionalizing a porous membrane covering of an optical sensor to facilitate coupling of an antithrombogenic agent |
| ES2959510T3 (en) | 2011-10-21 | 2024-02-26 | Icu Medical Inc | Medical device update system |
| WO2013066873A1 (en) | 2011-10-31 | 2013-05-10 | Abbott Diabetes Care Inc. | Electronic devices having integrated reset systems and methods thereof |
| US9622691B2 (en) | 2011-10-31 | 2017-04-18 | Abbott Diabetes Care Inc. | Model based variable risk false glucose threshold alarm prevention mechanism |
| US9989522B2 (en) | 2011-11-01 | 2018-06-05 | Medtronic Minimed, Inc. | Methods and materials for modulating start-up time and air removal in dry sensors |
| AU2012335830B2 (en) | 2011-11-07 | 2017-05-04 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods |
| US8999720B2 (en) | 2011-11-17 | 2015-04-07 | Medtronic Minimed, Inc. | Aqueous radiation protecting formulations and methods for making and using them |
| US8710993B2 (en) | 2011-11-23 | 2014-04-29 | Abbott Diabetes Care Inc. | Mitigating single point failure of devices in an analyte monitoring system and methods thereof |
| US9317656B2 (en) | 2011-11-23 | 2016-04-19 | Abbott Diabetes Care Inc. | Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof |
| WO2013078426A2 (en) | 2011-11-25 | 2013-05-30 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods of use |
| US10022498B2 (en) | 2011-12-16 | 2018-07-17 | Icu Medical, Inc. | System for monitoring and delivering medication to a patient and method of using the same to minimize the risks associated with automated therapy |
| US9610401B2 (en) | 2012-01-13 | 2017-04-04 | Medtronic Minimed, Inc. | Infusion set component with modular fluid channel element |
| PL2836943T3 (en) * | 2012-03-23 | 2020-07-13 | Dipartimento Di Ingegneria Civile E Architettura Dell'università Degli Studi Di Pavia | Method for providing a value of insulin and the related system |
| JP6306566B2 (en) | 2012-03-30 | 2018-04-04 | アイシーユー・メディカル・インコーポレーテッド | Air detection system and method for detecting air in an infusion system pump |
| CN104205105B (en) * | 2012-03-30 | 2018-08-17 | 皇家飞利浦有限公司 | Method for computer can be understood to the state of guide engine and the state synchronized of patient care |
| US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
| US9493807B2 (en) | 2012-05-25 | 2016-11-15 | Medtronic Minimed, Inc. | Foldover sensors and methods for making and using them |
| US9555186B2 (en) | 2012-06-05 | 2017-01-31 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
| US9238100B2 (en) | 2012-06-07 | 2016-01-19 | Tandem Diabetes Care, Inc. | Device and method for training users of ambulatory medical devices |
| US9632060B2 (en) | 2012-06-08 | 2017-04-25 | Medtronic Minimed, Inc. | Application of electrochemical impedance spectroscopy in sensor systems, devices, and related methods |
| EP2873014A4 (en) * | 2012-07-11 | 2016-04-27 | Caren Frances Thomson | Method, system and apparatus for setting insulin dosages for diabetics |
| US8768673B2 (en) | 2012-07-26 | 2014-07-01 | Rimidi Diabetes, Inc. | Computer-implemented system and method for improving glucose management through cloud-based modeling of circadian profiles |
| US8744828B2 (en) | 2012-07-26 | 2014-06-03 | Rimidi Diabetes, Inc. | Computer-implemented system and method for improving glucose management through modeling of circadian profiles |
| US8756043B2 (en) | 2012-07-26 | 2014-06-17 | Rimidi Diabetes, Inc. | Blood glucose meter and computer-implemented method for improving glucose management through modeling of circadian profiles |
| WO2014022513A1 (en) | 2012-07-31 | 2014-02-06 | Hospira, Inc. | Patient care system for critical medications |
| AR092077A1 (en) | 2012-08-10 | 2015-03-18 | Sanofi Aventis Deutschland | MEDICAL SYSTEM |
| US9682188B2 (en) | 2012-08-21 | 2017-06-20 | Medtronic Minimed, Inc. | Reservoir fluid volume estimator and medical device incorporating same |
| US9662445B2 (en) | 2012-08-30 | 2017-05-30 | Medtronic Minimed, Inc. | Regulating entry into a closed-loop operating mode of an insulin infusion system |
| US10132793B2 (en) | 2012-08-30 | 2018-11-20 | Abbott Diabetes Care Inc. | Dropout detection in continuous analyte monitoring data during data excursions |
| US10130767B2 (en) | 2012-08-30 | 2018-11-20 | Medtronic Minimed, Inc. | Sensor model supervisor for a closed-loop insulin infusion system |
| WO2014036177A1 (en) | 2012-08-30 | 2014-03-06 | Abbott Diabetes Care Inc. | Optimizing medication dosage based on analyte sensor data |
| US9897565B1 (en) * | 2012-09-11 | 2018-02-20 | Aseko, Inc. | System and method for optimizing insulin dosages for diabetic subjects |
| US9968306B2 (en) | 2012-09-17 | 2018-05-15 | Abbott Diabetes Care Inc. | Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems |
| US9907492B2 (en) | 2012-09-26 | 2018-03-06 | Abbott Diabetes Care Inc. | Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data |
| US10318915B2 (en) | 2012-09-26 | 2019-06-11 | Thuban, Inc. | Healthcare system for recording and monitoring transactions of system participants |
| WO2014055718A1 (en) * | 2012-10-04 | 2014-04-10 | Aptima, Inc. | Clinical support systems and methods |
| US10463282B2 (en) * | 2012-10-04 | 2019-11-05 | Roche Diabetes Care, Inc. | System and method for assessing risk associated with a glucose state |
| US9119529B2 (en) | 2012-10-30 | 2015-09-01 | Dexcom, Inc. | Systems and methods for dynamically and intelligently monitoring a host's glycemic condition after an alert is triggered |
| EP2916722A4 (en) | 2012-11-07 | 2016-07-20 | Medtronic Minimed Inc | Dry insertion and one-point in vivo calibration of an optical analyte sensor |
| US9833191B2 (en) | 2012-11-07 | 2017-12-05 | Bigfoot Biomedical, Inc. | Computer-based diabetes management |
| US9265455B2 (en) | 2012-11-13 | 2016-02-23 | Medtronic Minimed, Inc. | Methods and systems for optimizing sensor function by the application of voltage |
| US10194840B2 (en) | 2012-12-06 | 2019-02-05 | Medtronic Minimed, Inc. | Microarray electrodes useful with analyte sensors and methods for making and using them |
| US9907909B2 (en) * | 2012-12-20 | 2018-03-06 | Animas Corporation | Method and system for a hybrid control-to-target and control-to-range model predictive control of an artificial pancreas |
| US10383580B2 (en) | 2012-12-31 | 2019-08-20 | Abbott Diabetes Care Inc. | Analysis of glucose median, variability, and hypoglycemia risk for therapy guidance |
| US9351670B2 (en) | 2012-12-31 | 2016-05-31 | Abbott Diabetes Care Inc. | Glycemic risk determination based on variability of glucose levels |
| US10426383B2 (en) | 2013-01-22 | 2019-10-01 | Medtronic Minimed, Inc. | Muting glucose sensor oxygen response and reducing electrode edge growth with pulsed current plating |
| US9357961B2 (en) | 2013-02-22 | 2016-06-07 | Thuban, Inc. | Device for enabling patient self testing and treatment self- administration and system using the device for managing the patient's health care |
| ES2908320T3 (en) | 2013-03-06 | 2022-04-28 | Icu Medical Inc | Medical device communication method |
| US10357606B2 (en) | 2013-03-13 | 2019-07-23 | Tandem Diabetes Care, Inc. | System and method for integration of insulin pumps and continuous glucose monitoring |
| US10201656B2 (en) | 2013-03-13 | 2019-02-12 | Tandem Diabetes Care, Inc. | Simplified insulin pump for type II diabetics |
| US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
| WO2014152034A1 (en) | 2013-03-15 | 2014-09-25 | Abbott Diabetes Care Inc. | Sensor fault detection using analyte sensor data pattern comparison |
| US9474475B1 (en) | 2013-03-15 | 2016-10-25 | Abbott Diabetes Care Inc. | Multi-rate analyte sensor data collection with sample rate configurable signal processing |
| US9492608B2 (en) | 2013-03-15 | 2016-11-15 | Tandem Diabetes Care, Inc. | Method and device utilizing insulin delivery protocols |
| US10433773B1 (en) | 2013-03-15 | 2019-10-08 | Abbott Diabetes Care Inc. | Noise rejection methods and apparatus for sparsely sampled analyte sensor data |
| AU2014233094B2 (en) | 2013-03-15 | 2020-07-02 | Abbott Diabetes Care Inc. | System and method to manage diabetes based on glucose median, glucose variability, and hypoglycemic risk |
| US10016561B2 (en) | 2013-03-15 | 2018-07-10 | Tandem Diabetes Care, Inc. | Clinical variable determination |
| CA2913421C (en) | 2013-05-24 | 2022-02-15 | Hospira, Inc. | Multi-sensor infusion system for detecting air or an occlusion in the infusion system |
| CA2913915C (en) | 2013-05-29 | 2022-03-29 | Hospira, Inc. | Infusion system which utilizes one or more sensors and additional information to make an air determination regarding the infusion system |
| US9338819B2 (en) | 2013-05-29 | 2016-05-10 | Medtronic Minimed, Inc. | Variable data usage personal medical system and method |
| CA2913918C (en) | 2013-05-29 | 2022-02-15 | Hospira, Inc. | Infusion system and method of use which prevents over-saturation of an analog-to-digital converter |
| US10194864B2 (en) | 2013-06-21 | 2019-02-05 | Medtronic Minimed, Inc. | Anchoring apparatus and method for attaching device on body |
| US10339272B2 (en) * | 2013-06-26 | 2019-07-02 | Sanofi | System and method for patient care improvement |
| US9561324B2 (en) | 2013-07-19 | 2017-02-07 | Bigfoot Biomedical, Inc. | Infusion pump system and method |
| WO2015009385A1 (en) | 2013-07-19 | 2015-01-22 | Dexcom, Inc. | Time averaged basal rate optimizer |
| US9880528B2 (en) | 2013-08-21 | 2018-01-30 | Medtronic Minimed, Inc. | Medical devices and related updating methods and systems |
| EP3039596A4 (en) | 2013-08-30 | 2017-04-12 | Hospira, Inc. | System and method of monitoring and managing a remote infusion regimen |
| US9662436B2 (en) | 2013-09-20 | 2017-05-30 | Icu Medical, Inc. | Fail-safe drug infusion therapy system |
| US8979808B1 (en) | 2013-10-14 | 2015-03-17 | Medtronic Minimed, Inc. | On-body injector and method of use |
| US9375537B2 (en) | 2013-10-14 | 2016-06-28 | Medtronic Minimed, Inc. | Therapeutic agent injection device |
| US9265881B2 (en) | 2013-10-14 | 2016-02-23 | Medtronic Minimed, Inc. | Therapeutic agent injection device |
| US8979799B1 (en) | 2013-10-14 | 2015-03-17 | Medtronic Minimed, Inc. | Electronic injector |
| US10076283B2 (en) | 2013-11-04 | 2018-09-18 | Medtronic, Inc. | Method and device to manage fluid volumes in the body |
| US9226709B2 (en) | 2013-11-04 | 2016-01-05 | Medtronic Minimed, Inc. | ICE message system and method |
| US10311972B2 (en) | 2013-11-11 | 2019-06-04 | Icu Medical, Inc. | Medical device system performance index |
| TR201908852T4 (en) | 2013-11-19 | 2019-07-22 | Icu Medical Inc | Infusion pump automation system and method. |
| US9267875B2 (en) | 2013-11-21 | 2016-02-23 | Medtronic Minimed, Inc. | Accelerated life testing device and method |
| EP3073911A4 (en) | 2013-11-27 | 2017-07-19 | Medtronic Inc. | Precision dialysis monitoring and synchonization system |
| US10569015B2 (en) * | 2013-12-02 | 2020-02-25 | Bigfoot Biomedical, Inc. | Infusion pump system and method |
| US9750877B2 (en) | 2013-12-11 | 2017-09-05 | Medtronic Minimed, Inc. | Predicted time to assess and/or control a glycemic state |
| US9849240B2 (en) | 2013-12-12 | 2017-12-26 | Medtronic Minimed, Inc. | Data modification for predictive operations and devices incorporating same |
| US10105488B2 (en) | 2013-12-12 | 2018-10-23 | Medtronic Minimed, Inc. | Predictive infusion device operations and related methods and systems |
| US20150164382A1 (en) | 2013-12-16 | 2015-06-18 | Medtronic Minimed, Inc. | Use of electrochemical impedance spectroscopy (eis) in continuous glucose monitoring |
| US20150164385A1 (en) | 2013-12-16 | 2015-06-18 | Medtronic Minimed, Inc. | Methods and systems for improving the reliability of orthogonally redundant sensors |
| US9143941B2 (en) | 2013-12-18 | 2015-09-22 | Medtronic Minimed, Inc. | Secure communication by user selectable communication range |
| US9779226B2 (en) | 2013-12-18 | 2017-10-03 | Medtronic Minimed, Inc. | Fingerprint enhanced authentication for medical devices in wireless networks |
| US9694132B2 (en) | 2013-12-19 | 2017-07-04 | Medtronic Minimed, Inc. | Insertion device for insertion set |
| EP3086828B1 (en) | 2013-12-26 | 2023-08-09 | Tandem Diabetes Care, Inc. | Integration of infusion pump with remote electronic device |
| RU2683203C2 (en) | 2013-12-31 | 2019-03-26 | Эбботт Дайабитиз Кэр Инк. | Self-powered analyte sensor and devices using the same |
| EP3100189A1 (en) * | 2014-01-28 | 2016-12-07 | Debiotech S.A. | Control device with recommendations |
| GB2523989B (en) | 2014-01-30 | 2020-07-29 | Insulet Netherlands B V | Therapeutic product delivery system and method of pairing |
| US9486580B2 (en) | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
| US9233204B2 (en) * | 2014-01-31 | 2016-01-12 | Aseko, Inc. | Insulin management |
| US9861748B2 (en) | 2014-02-06 | 2018-01-09 | Medtronic Minimed, Inc. | User-configurable closed-loop notifications and infusion systems incorporating same |
| WO2015131108A2 (en) | 2014-02-28 | 2015-09-03 | Hospira, Inc. | Infusion system and method which utilizes dual wavelength optical air-in-line detection |
| US9388805B2 (en) | 2014-03-24 | 2016-07-12 | Medtronic Minimed, Inc. | Medication pump test device and method of use |
| US20170185748A1 (en) | 2014-03-30 | 2017-06-29 | Abbott Diabetes Care Inc. | Method and Apparatus for Determining Meal Start and Peak Events in Analyte Monitoring Systems |
| US9689830B2 (en) | 2014-04-03 | 2017-06-27 | Medtronic Minimed, Inc. | Sensor detection pads with integrated fuse |
| US9707336B2 (en) | 2014-04-07 | 2017-07-18 | Medtronic Minimed, Inc. | Priming detection system and method of using the same |
| US10004845B2 (en) | 2014-04-18 | 2018-06-26 | Becton, Dickinson And Company | Split piston metering pump |
| US10232113B2 (en) | 2014-04-24 | 2019-03-19 | Medtronic Minimed, Inc. | Infusion devices and related methods and systems for regulating insulin on board |
| CA2945647C (en) | 2014-04-30 | 2023-08-08 | Hospira, Inc. | Patient care system with conditional alarm forwarding |
| US9681828B2 (en) | 2014-05-01 | 2017-06-20 | Medtronic Minimed, Inc. | Physiological characteristic sensors and methods for forming such sensors |
| WO2015184366A1 (en) | 2014-05-29 | 2015-12-03 | Hospira, Inc. | Infusion system and pump with configurable closed loop delivery rate catch-up |
| WO2015191459A1 (en) | 2014-06-10 | 2015-12-17 | Bigfoot Biomedical, Inc. | Insulin delivery systems and methods |
| US9901305B2 (en) | 2014-06-13 | 2018-02-27 | Medtronic Minimed, Inc. | Physiological sensor history backfill system and method |
| US9724470B2 (en) | 2014-06-16 | 2017-08-08 | Icu Medical, Inc. | System for monitoring and delivering medication to a patient and method of using the same to minimize the risks associated with automated therapy |
| US9416775B2 (en) | 2014-07-02 | 2016-08-16 | Becton, Dickinson And Company | Internal cam metering pump |
| EP2966582A1 (en) | 2014-07-11 | 2016-01-13 | Sanofi-Aventis Deutschland GmbH | Titration of basal insulin with two modes |
| US10532150B2 (en) | 2014-07-21 | 2020-01-14 | Medtronic Minimed, Inc. | Smart connection interface |
| WO2016019133A1 (en) | 2014-07-30 | 2016-02-04 | Tandem Diabetes Care, Inc. | Temporary suspension for closed-loop medicament therapy |
| US9717845B2 (en) | 2014-08-19 | 2017-08-01 | Medtronic Minimed, Inc. | Geofencing for medical devices |
| US20160051755A1 (en) | 2014-08-25 | 2016-02-25 | Medtronic Minimed, Inc. | Low cost fluid delivery device |
| US9539383B2 (en) | 2014-09-15 | 2017-01-10 | Hospira, Inc. | System and method that matches delayed infusion auto-programs with manually entered infusion programs and analyzes differences therein |
| US9839753B2 (en) | 2014-09-26 | 2017-12-12 | Medtronic Minimed, Inc. | Systems for managing reservoir chamber pressure |
| US10279126B2 (en) | 2014-10-07 | 2019-05-07 | Medtronic Minimed, Inc. | Fluid conduit assembly with gas trapping filter in the fluid flow path |
| US9592335B2 (en) | 2014-10-20 | 2017-03-14 | Medtronic Minimed, Inc. | Insulin pump data acquisition device |
| US9841014B2 (en) | 2014-10-20 | 2017-12-12 | Medtronic Minimed, Inc. | Insulin pump data acquisition device and system |
| EP3050023B1 (en) | 2014-10-27 | 2021-08-25 | Aseko, Inc. | Subcutaneous outpatient management |
| US11081226B2 (en) * | 2014-10-27 | 2021-08-03 | Aseko, Inc. | Method and controller for administering recommended insulin dosages to a patient |
| CN105688308A (en) * | 2014-11-13 | 2016-06-22 | 上海泽生科技开发有限公司 | An injection pump control method and control unit and an injection pump |
| US9731067B2 (en) | 2014-11-25 | 2017-08-15 | Medtronic Minimed, Inc. | Mechanical injection pump and method of use |
| US9901675B2 (en) | 2014-11-25 | 2018-02-27 | Medtronic Minimed, Inc. | Infusion set insertion device and method of use |
| US9943645B2 (en) | 2014-12-04 | 2018-04-17 | Medtronic Minimed, Inc. | Methods for operating mode transitions and related infusion devices and systems |
| US9636453B2 (en) | 2014-12-04 | 2017-05-02 | Medtronic Minimed, Inc. | Advance diagnosis of infusion device operating mode viability |
| US11344668B2 (en) | 2014-12-19 | 2022-05-31 | Icu Medical, Inc. | Infusion system with concurrent TPN/insulin infusion |
| US10307535B2 (en) | 2014-12-19 | 2019-06-04 | Medtronic Minimed, Inc. | Infusion devices and related methods and systems for preemptive alerting |
| US9717848B2 (en) | 2015-01-22 | 2017-08-01 | Medtronic Minimed, Inc. | Data derived pre-bolus delivery |
| CA2977053C (en) | 2015-02-18 | 2023-08-01 | Insulet Corporation | Fluid delivery and infusion devices, and methods of use thereof |
| US10850024B2 (en) | 2015-03-02 | 2020-12-01 | Icu Medical, Inc. | Infusion system, device, and method having advanced infusion features |
| US9872954B2 (en) | 2015-03-02 | 2018-01-23 | Medtronic Minimed, Inc. | Belt clip |
| US10307528B2 (en) | 2015-03-09 | 2019-06-04 | Medtronic Minimed, Inc. | Extensible infusion devices and related methods |
| US10449298B2 (en) | 2015-03-26 | 2019-10-22 | Medtronic Minimed, Inc. | Fluid injection devices and related methods |
| US9878097B2 (en) | 2015-04-29 | 2018-01-30 | Bigfoot Biomedical, Inc. | Operating an infusion pump system |
| US10130757B2 (en) | 2015-05-01 | 2018-11-20 | Medtronic Minimed, Inc. | Method and system for leakage detection in portable medical devices |
| US10064994B2 (en) | 2015-05-22 | 2018-09-04 | Iowa State University Research Foundation, Inc. | Automatic insulin delivery system |
| EP3304370B1 (en) | 2015-05-26 | 2020-12-30 | ICU Medical, Inc. | Infusion pump system and method with multiple drug library editor source capability |
| US9999721B2 (en) | 2015-05-26 | 2018-06-19 | Medtronic Minimed, Inc. | Error handling in infusion devices with distributed motor control and related operating methods |
| US11311665B2 (en) * | 2015-06-09 | 2022-04-26 | University Of Virginia Patent Foundation | Insulin monitoring and delivery system and method for CGM based fault detection and mitigation via metabolic state tracking |
| CA2991716A1 (en) | 2015-07-10 | 2017-01-19 | Abbott Diabetes Care Inc. | System, device and method of dynamic glucose profile response to physiological parameters |
| WO2017027432A1 (en) | 2015-08-07 | 2017-02-16 | Aptima, Inc. | Systems and methods to support medical therapy decisions |
| DK3319511T3 (en) | 2015-08-07 | 2021-11-01 | Univ Boston | Glucose management system with automatic adjustment of glucose targets |
| CA2993275C (en) | 2015-08-20 | 2022-06-21 | Aseko, Inc. | Diabetes management therapy advisor |
| US10293108B2 (en) | 2015-08-21 | 2019-05-21 | Medtronic Minimed, Inc. | Infusion devices and related patient ratio adjustment methods |
| US10201657B2 (en) | 2015-08-21 | 2019-02-12 | Medtronic Minimed, Inc. | Methods for providing sensor site rotation feedback and related infusion devices and systems |
| US10478557B2 (en) | 2015-08-21 | 2019-11-19 | Medtronic Minimed, Inc. | Personalized parameter modeling methods and related devices and systems |
| US10117992B2 (en) | 2015-09-29 | 2018-11-06 | Medtronic Minimed, Inc. | Infusion devices and related rescue detection methods |
| US9992818B2 (en) | 2015-10-06 | 2018-06-05 | Medtronic Minimed, Inc. | Protocol translation device |
| US9757511B2 (en) | 2015-10-19 | 2017-09-12 | Medtronic Minimed, Inc. | Personal medical device and method of use with restricted mode challenge |
| US11501867B2 (en) | 2015-10-19 | 2022-11-15 | Medtronic Minimed, Inc. | Medical devices and related event pattern presentation methods |
| US11666702B2 (en) | 2015-10-19 | 2023-06-06 | Medtronic Minimed, Inc. | Medical devices and related event pattern treatment recommendation methods |
| US10146911B2 (en) | 2015-10-23 | 2018-12-04 | Medtronic Minimed, Inc. | Medical devices and related methods and systems for data transfer |
| US10037722B2 (en) | 2015-11-03 | 2018-07-31 | Medtronic Minimed, Inc. | Detecting breakage in a display element |
| US10335534B2 (en) | 2015-11-06 | 2019-07-02 | Medtronic, Inc. | Dialysis prescription optimization for decreased arrhythmias |
| US10827959B2 (en) | 2015-11-11 | 2020-11-10 | Medtronic Minimed, Inc. | Sensor set |
| US9848805B2 (en) | 2015-12-18 | 2017-12-26 | Medtronic Minimed, Inc. | Biostable glucose permeable polymer |
| US20170181672A1 (en) | 2015-12-28 | 2017-06-29 | Medtronic Minimed, Inc. | Sensor systems, devices, and methods for continuous glucose monitoring |
| US10327686B2 (en) | 2015-12-28 | 2019-06-25 | Medtronic Minimed, Inc. | Sensor systems, devices, and methods for continuous glucose monitoring |
| US10349872B2 (en) | 2015-12-28 | 2019-07-16 | Medtronic Minimed, Inc. | Methods, systems, and devices for sensor fusion |
| US10327680B2 (en) | 2015-12-28 | 2019-06-25 | Medtronic Minimed, Inc. | Sensor systems, devices, and methods for continuous glucose monitoring |
| US10569016B2 (en) | 2015-12-29 | 2020-02-25 | Tandem Diabetes Care, Inc. | System and method for switching between closed loop and open loop control of an ambulatory infusion pump |
| US10449294B1 (en) | 2016-01-05 | 2019-10-22 | Bigfoot Biomedical, Inc. | Operating an infusion pump system |
| CA3009409A1 (en) | 2016-01-05 | 2017-07-13 | Bigfoot Biomedical, Inc. | Operating multi-modal medicine delivery systems |
| JP6957509B2 (en) * | 2016-01-12 | 2021-11-02 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Predictive control model for artificial pancreas using past predictions |
| EP3374905A1 (en) | 2016-01-13 | 2018-09-19 | Bigfoot Biomedical, Inc. | User interface for diabetes management system |
| CN108495665B (en) | 2016-01-14 | 2021-04-09 | 比格福特生物医药公司 | Adjusting insulin delivery rate |
| CA3013053A1 (en) | 2016-01-28 | 2017-08-03 | Savor Labs, Inc. | Method and apparatus for tracking of food intake and other behaviors and providing relevant feedback |
| US10790054B1 (en) | 2016-12-07 | 2020-09-29 | Medtronic Minimed, Inc. | Method and apparatus for tracking of food intake and other behaviors and providing relevant feedback |
| US20170263156A1 (en) * | 2016-03-08 | 2017-09-14 | Quattro Folia Oy | Method and system for recommending a set of insulin dosages for a patient |
| US10994064B2 (en) | 2016-08-10 | 2021-05-04 | Medtronic, Inc. | Peritoneal dialysate flow path sensing |
| US10874790B2 (en) | 2016-08-10 | 2020-12-29 | Medtronic, Inc. | Peritoneal dialysis intracycle osmotic agent adjustment |
| US10765369B2 (en) | 2016-04-08 | 2020-09-08 | Medtronic Minimed, Inc. | Analyte sensor |
| US10420508B2 (en) | 2016-04-08 | 2019-09-24 | Medtronic Minimed, Inc. | Sensor connections |
| US10765348B2 (en) | 2016-04-08 | 2020-09-08 | Medtronic Minimed, Inc. | Sensor and transmitter product |
| US10589038B2 (en) | 2016-04-27 | 2020-03-17 | Medtronic Minimed, Inc. | Set connector systems for venting a fluid reservoir |
| US10324058B2 (en) | 2016-04-28 | 2019-06-18 | Medtronic Minimed, Inc. | In-situ chemistry stack for continuous glucose sensors |
| US10426389B2 (en) | 2016-04-28 | 2019-10-01 | Medtronic Minimed, Inc. | Methods, systems, and devices for electrode capacitance calculation and application |
| US9970893B2 (en) | 2016-04-28 | 2018-05-15 | Medtronic Minimed, Inc. | Methods, systems, and devices for electrode capacitance calculation and application |
| CA3023658C (en) | 2016-05-13 | 2023-03-07 | Icu Medical, Inc. | Infusion pump system and method with common line auto flush |
| US10086133B2 (en) | 2016-05-26 | 2018-10-02 | Medtronic Minimed, Inc. | Systems for set connector assembly with lock |
| US9968737B2 (en) | 2016-05-26 | 2018-05-15 | Medtronic Minimed, Inc. | Systems for set connector assembly with lock |
| US10086134B2 (en) | 2016-05-26 | 2018-10-02 | Medtronic Minimed, Inc. | Systems for set connector assembly with lock |
| US11179078B2 (en) | 2016-06-06 | 2021-11-23 | Medtronic Minimed, Inc. | Polycarbonate urea/urethane polymers for use with analyte sensors |
| US11134872B2 (en) | 2016-06-06 | 2021-10-05 | Medtronic Minimed, Inc. | Thermally stable glucose limiting membrane for glucose sensors |
| CA3027176A1 (en) | 2016-06-10 | 2017-12-14 | Icu Medical, Inc. | Acoustic flow sensor for continuous medication flow measurements and feedback control of infusion |
| MA45601A (en) | 2016-07-08 | 2019-05-15 | Novo Nordisk As | SYSTEMS AND METHODS FOR DETERMINING SUSCEPTIBILITY TO INSULIN |
| EP3481274B1 (en) | 2016-07-08 | 2023-01-25 | Novo Nordisk A/S | Basal titration with adaptive target glucose level |
| CA3030786A1 (en) | 2016-07-14 | 2018-01-18 | Icu Medical, Inc. | Multi-communication path selection and security system for a medical device |
| US11617832B2 (en) | 2016-08-17 | 2023-04-04 | International Business Machines Corporation | Portal system-based bionic pancreas |
| US10485924B2 (en) | 2016-09-06 | 2019-11-26 | Medtronic Minimed, Inc. | Pump clip for a fluid infusion device |
| US11013843B2 (en) | 2016-09-09 | 2021-05-25 | Medtronic, Inc. | Peritoneal dialysis fluid testing system |
| US10765807B2 (en) | 2016-09-23 | 2020-09-08 | Insulet Corporation | Fluid delivery device with sensor |
| US10426896B2 (en) | 2016-09-27 | 2019-10-01 | Bigfoot Biomedical, Inc. | Medicine injection and disease management systems, devices, and methods |
| US10792421B2 (en) | 2016-10-05 | 2020-10-06 | Iowa State University Research Foundation, Inc. | Automatic insulin delivery system with minimized input variable lag |
| CA3037432A1 (en) | 2016-12-12 | 2018-06-21 | Bigfoot Biomedical, Inc. | Alarms and alerts for medication delivery devices and related systems and methods |
| US10709834B2 (en) | 2016-12-21 | 2020-07-14 | Medtronic Minimed, Inc. | Medication fluid infusion set component with integrated physiological analyte sensor, and corresponding fluid infusion device |
| US10783801B1 (en) | 2016-12-21 | 2020-09-22 | Aptima, Inc. | Simulation based training system for measurement of team cognitive load to automatically customize simulation content |
| US10854323B2 (en) | 2016-12-21 | 2020-12-01 | Medtronic Minimed, Inc. | Infusion systems and related personalized bolusing methods |
| US10272201B2 (en) | 2016-12-22 | 2019-04-30 | Medtronic Minimed, Inc. | Insertion site monitoring methods and related infusion devices and systems |
| JP7196077B2 (en) | 2016-12-23 | 2022-12-26 | サノフィ－アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Data management unit to support health management |
| CN110235205A (en) | 2016-12-23 | 2019-09-13 | 赛诺菲-安万特德国有限公司 | Data Management Unit for supporting health to control |
| JP7146764B2 (en) | 2016-12-23 | 2022-10-04 | サノフィ－アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Data management unit to support health management |
| US10758675B2 (en) | 2017-01-13 | 2020-09-01 | Bigfoot Biomedical, Inc. | System and method for adjusting insulin delivery |
| EP3568859A1 (en) | 2017-01-13 | 2019-11-20 | Bigfoot Biomedical, Inc. | Insulin delivery methods, systems and devices |
| WO2018132754A1 (en) | 2017-01-13 | 2018-07-19 | Mazlish Bryan | System and method for adjusting insulin delivery |
| US10583250B2 (en) | 2017-01-13 | 2020-03-10 | Bigfoot Biomedical, Inc. | System and method for adjusting insulin delivery |
| EP3568860A1 (en) | 2017-01-13 | 2019-11-20 | Bigfoot Biomedical, Inc. | Insulin delivery methods, systems and devices |
| US10500334B2 (en) | 2017-01-13 | 2019-12-10 | Bigfoot Biomedical, Inc. | System and method for adjusting insulin delivery |
| US11197949B2 (en) | 2017-01-19 | 2021-12-14 | Medtronic Minimed, Inc. | Medication infusion components and systems |
| US10821225B2 (en) | 2017-01-20 | 2020-11-03 | Medtronic Minimed, Inc. | Cannulas for drug delivery devices |
| US10552580B2 (en) | 2017-02-07 | 2020-02-04 | Medtronic Minimed, Inc. | Infusion system consumables and related calibration methods |
| US10646649B2 (en) | 2017-02-21 | 2020-05-12 | Medtronic Minimed, Inc. | Infusion devices and fluid identification apparatuses and methods |
| US11134868B2 (en) | 2017-03-17 | 2021-10-05 | Medtronic Minimed, Inc. | Metal pillar device structures and methods for making and using them in electrochemical and/or electrocatalytic applications |
| EP3600014A4 (en) | 2017-03-21 | 2020-10-21 | Abbott Diabetes Care Inc. | Methods, devices and system for providing diabetic condition diagnosis and therapy |
| US20180272066A1 (en) | 2017-03-24 | 2018-09-27 | Medtronic Minimed, Inc. | Patient management systems and adherence recommendation methods |
| US10729849B2 (en) * | 2017-04-07 | 2020-08-04 | LifeSpan IP Holdings, LLC | Insulin-on-board accounting in an artificial pancreas system |
| CN110582231B (en) * | 2017-05-05 | 2023-05-16 | 伊莱利利公司 | Closed loop control of physiological glucose |
| US20180328877A1 (en) | 2017-05-11 | 2018-11-15 | Medtronic Minimed, Inc. | Analyte sensors and methods for fabricating analyte sensors |
| US10856784B2 (en) | 2017-06-30 | 2020-12-08 | Medtronic Minimed, Inc. | Sensor initialization methods for faster body sensor response |
| US10596295B2 (en) | 2017-08-28 | 2020-03-24 | Medtronic Minimed, Inc. | Adhesive patch arrangement for a physiological characteristic sensor, and related sensor assembly |
| US11412960B2 (en) | 2017-08-28 | 2022-08-16 | Medtronic Minimed, Inc. | Pedestal for sensor assembly packaging and sensor introducer removal |
| US11344235B2 (en) | 2017-09-13 | 2022-05-31 | Medtronic Minimed, Inc. | Methods, systems, and devices for calibration and optimization of glucose sensors and sensor output |
| US10874300B2 (en) | 2017-09-26 | 2020-12-29 | Medtronic Minimed, Inc. | Waferscale physiological characteristic sensor package with integrated wireless transmitter |
| US10525244B2 (en) | 2017-09-28 | 2020-01-07 | Medtronic Minimed, Inc. | Microneedle arrays and methods for fabricating microneedle arrays |
| US10524730B2 (en) | 2017-09-28 | 2020-01-07 | Medtronic Minimed, Inc. | Medical devices with microneedle arrays and methods for operating such medical devices |
| US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
| CN111246797A (en) | 2017-10-24 | 2020-06-05 | 德克斯康公司 | Pre-attached analyte sensors |
| RU2661724C1 (en) * | 2017-10-30 | 2018-07-19 | Виль Закирович Рахманкулов | Device for automatic identification and correction of patients with diabetes mellitus |
| US11676734B2 (en) | 2017-11-15 | 2023-06-13 | Medtronic Minimed, Inc. | Patient therapy management system that leverages aggregated patient population data |
| US11464459B2 (en) | 2017-12-12 | 2022-10-11 | Bigfoot Biomedical, Inc. | User interface for diabetes management systems including flash glucose monitor |
| US10987464B2 (en) | 2017-12-12 | 2021-04-27 | Bigfoot Biomedical, Inc. | Pen cap for insulin injection pens and associated methods and systems |
| US11116899B2 (en) | 2017-12-12 | 2021-09-14 | Bigfoot Biomedical, Inc. | User interface for diabetes management systems and devices |
| US11077243B2 (en) | 2017-12-12 | 2021-08-03 | Bigfoot Biomedical, Inc. | Devices, systems, and methods for estimating active medication from injections |
| EP3724891A1 (en) | 2017-12-12 | 2020-10-21 | Bigfoot Biomedical, Inc. | Medicine injection and disease management systems, devices, and methods |
| US11471082B2 (en) | 2017-12-13 | 2022-10-18 | Medtronic Minimed, Inc. | Complex redundancy in continuous glucose monitoring |
| US11213230B2 (en) | 2017-12-13 | 2022-01-04 | Medtronic Minimed, Inc. | Optional sensor calibration in continuous glucose monitoring |
| CN111542884B (en) | 2017-12-21 | 2024-03-15 | 益首药物治疗股份公司 | Closed loop control of physiological glucose |
| US10089055B1 (en) | 2017-12-27 | 2018-10-02 | Icu Medical, Inc. | Synchronized display of screen content on networked devices |
| US11439352B2 (en) | 2018-01-17 | 2022-09-13 | Medtronic Minimed, Inc. | Medical device with adhesive patch longevity |
| US11186859B2 (en) | 2018-02-07 | 2021-11-30 | Medtronic Minimed, Inc. | Multilayer electrochemical analyte sensors and methods for making and using them |
| US11220735B2 (en) | 2018-02-08 | 2022-01-11 | Medtronic Minimed, Inc. | Methods for controlling physical vapor deposition metal film adhesion to substrates and surfaces |
| US11583213B2 (en) | 2018-02-08 | 2023-02-21 | Medtronic Minimed, Inc. | Glucose sensor electrode design |
| US11672446B2 (en) | 2018-03-23 | 2023-06-13 | Medtronic Minimed, Inc. | Insulin delivery recommendations based on nutritional information |
| USD911355S1 (en) | 2018-03-29 | 2021-02-23 | Bigfoot Biomedical, Inc. | Display screen or portion thereof with graphical user interface |
| USD928199S1 (en) | 2018-04-02 | 2021-08-17 | Bigfoot Biomedical, Inc. | Medication delivery device with icons |
| US11872368B2 (en) | 2018-04-10 | 2024-01-16 | Tandem Diabetes Care, Inc. | System and method for inductively charging a medical device |
| US11147919B2 (en) | 2018-04-23 | 2021-10-19 | Medtronic Minimed, Inc. | Methodology to recommend and implement adjustments to a fluid infusion device of a medication delivery system |
| US11158413B2 (en) | 2018-04-23 | 2021-10-26 | Medtronic Minimed, Inc. | Personalized closed loop medication delivery system that utilizes a digital twin of the patient |
| EP3788628A1 (en) | 2018-05-04 | 2021-03-10 | Insulet Corporation | Safety constraints for a control algorithm-based drug delivery system |
| US20190341149A1 (en) | 2018-05-07 | 2019-11-07 | Medtronic Minimed, Inc. | Augmented reality guidance for medical devices |
| US11147922B2 (en) | 2018-07-13 | 2021-10-19 | Iowa State University Research Foundation, Inc. | Feedback predictive control approach for processes with time delay in the manipulated variable |
| WO2020018389A1 (en) | 2018-07-17 | 2020-01-23 | Icu Medical, Inc. | Systems and methods for facilitating clinical messaging in a network environment |
| US10861592B2 (en) | 2018-07-17 | 2020-12-08 | Icu Medical, Inc. | Reducing infusion pump network congestion by staggering updates |
| US10741280B2 (en) | 2018-07-17 | 2020-08-11 | Icu Medical, Inc. | Tagging pump messages with identifiers that facilitate restructuring |
| WO2020018388A1 (en) | 2018-07-17 | 2020-01-23 | Icu Medical, Inc. | Updating infusion pump drug libraries and operational software in a networked environment |
| EP3827337A4 (en) | 2018-07-26 | 2022-04-13 | ICU Medical, Inc. | Drug library management system |
| US10692595B2 (en) | 2018-07-26 | 2020-06-23 | Icu Medical, Inc. | Drug library dynamic version management |
| US11761077B2 (en) | 2018-08-01 | 2023-09-19 | Medtronic Minimed, Inc. | Sputtering techniques for biosensors |
| US11122697B2 (en) | 2018-08-07 | 2021-09-14 | Medtronic Minimed, Inc. | Method of fabricating an electronic medical device, including overmolding an assembly with thermoplastic material |
| US11021731B2 (en) | 2018-08-23 | 2021-06-01 | Medtronic Minimed, Inc. | Analyte sensing layers, analyte sensors and methods for fabricating the same |
| US10828419B2 (en) | 2018-09-04 | 2020-11-10 | Medtronic Minimed, Inc. | Infusion set with pivoting metal cannula and strain relief |
| US11547799B2 (en) | 2018-09-20 | 2023-01-10 | Medtronic Minimed, Inc. | Patient day planning systems and methods |
| US11071821B2 (en) | 2018-09-28 | 2021-07-27 | Medtronic Minimed, Inc. | Insulin infusion device with efficient confirmation routine for blood glucose measurements |
| CA3112209C (en) | 2018-09-28 | 2023-08-29 | Insulet Corporation | Activity mode for artificial pancreas system |
| US10980942B2 (en) | 2018-09-28 | 2021-04-20 | Medtronic Minimed, Inc. | Infusion devices and related meal bolus adjustment methods |
| US11097052B2 (en) | 2018-09-28 | 2021-08-24 | Medtronic Minimed, Inc. | Insulin infusion device with configurable target blood glucose value for automatic basal insulin delivery operation |
| US10894126B2 (en) | 2018-09-28 | 2021-01-19 | Medtronic Minimed, Inc. | Fluid infusion system that automatically determines and delivers a correction bolus |
| US10946140B2 (en) | 2018-10-11 | 2021-03-16 | Medtronic Minimed, Inc. | Systems and methods for measurement of fluid delivery |
| WO2020077223A1 (en) | 2018-10-11 | 2020-04-16 | Insulet Corporation | Event detection for drug delivery system |
| US20200116748A1 (en) | 2018-10-11 | 2020-04-16 | Medtronic Minimed, Inc. | Systems and methods for measurement of fluid delivery |
| US20200289373A1 (en) | 2018-10-31 | 2020-09-17 | Medtronic Minimed, Inc. | Automated detection of a physical behavior event and corresponding adjustment of a physiological characteristic sensor device |
| US11367517B2 (en) | 2018-10-31 | 2022-06-21 | Medtronic Minimed, Inc. | Gesture-based detection of a physical behavior event based on gesture sensor data and supplemental information from at least one external source |
| US20200135320A1 (en) | 2018-10-31 | 2020-04-30 | Medtronic Minimed, Inc. | Automated detection of a physical behavior event and corresponding adjustment of a medication dispensing system based on historical events |
| US11363986B2 (en) | 2018-10-31 | 2022-06-21 | Medtronic Minimed, Inc. | Automated detection of a physical behavior event and corresponding adjustment of a medication dispensing system |
| US11806457B2 (en) | 2018-11-16 | 2023-11-07 | Mozarc Medical Us Llc | Peritoneal dialysis adequacy meaurements |
| US11382541B2 (en) | 2018-11-16 | 2022-07-12 | Medtronic Minimed, Inc. | Miniaturized analyte sensor |
| US11806456B2 (en) | 2018-12-10 | 2023-11-07 | Mozarc Medical Us Llc | Precision peritoneal dialysis therapy based on dialysis adequacy measurements |
| US11540750B2 (en) | 2018-12-19 | 2023-01-03 | Medtronic Minimed, Inc | Systems and methods for physiological characteristic monitoring |
| CA3125268A1 (en) | 2018-12-28 | 2020-07-02 | Dexcom, Inc. | Evaluation and visualization of glycemic dysfunction |
| US11701467B2 (en) | 2019-02-01 | 2023-07-18 | Medtronic Minimed, Inc. | Methods and devices for occlusion detection using actuator sensors |
| US11389587B2 (en) | 2019-02-06 | 2022-07-19 | Medtronic Minimed, Inc. | Patient monitoring systems and related presentation methods |
| US11191899B2 (en) | 2019-02-12 | 2021-12-07 | Medtronic Minimed, Inc. | Infusion systems and related personalized bolusing methods |
| US11311215B2 (en) | 2019-04-04 | 2022-04-26 | Medtronic Minimed, Inc. | Measurement of device materials using non-Faradaic electrochemical impedance spectroscopy |
| US11317867B2 (en) | 2019-04-23 | 2022-05-03 | Medtronic Minimed, Inc. | Flexible physiological characteristic sensor assembly |
| US11224361B2 (en) | 2019-04-23 | 2022-01-18 | Medtronic Minimed, Inc. | Flexible physiological characteristic sensor assembly |
| US10939488B2 (en) | 2019-05-20 | 2021-03-02 | Medtronic Minimed, Inc. | Method and system for controlling communication between devices of a wireless body area network for an medical device system |
| US11844925B2 (en) | 2019-06-06 | 2023-12-19 | Medtronic Minimed, Inc. | Fluid infusion systems |
| US11448611B2 (en) | 2019-07-03 | 2022-09-20 | Medtronic Minimed, Inc. | Structurally reinforced sensor and method for manufacturing the same |
| AU2020314831A1 (en) | 2019-07-16 | 2022-02-24 | Beta Bionics, Inc. | Blood glucose control system |
| MX2022000669A (en) | 2019-07-16 | 2022-08-22 | Beta Bionics Inc | Blood glucose control system. |
| US11617828B2 (en) | 2019-07-17 | 2023-04-04 | Medtronic Minimed, Inc. | Reservoir connection interface with detectable signature |
| US11718865B2 (en) | 2019-07-26 | 2023-08-08 | Medtronic Minimed, Inc. | Methods to improve oxygen delivery to implantable sensors |
| US11523757B2 (en) | 2019-08-01 | 2022-12-13 | Medtronic Minimed, Inc. | Micro-pillar working electrodes design to reduce backflow of hydrogen peroxide in glucose sensor |
| AU2020324387A1 (en) * | 2019-08-02 | 2022-02-10 | Abbott Diabetes Care Inc. | Systems, devices, and methods relating to medication dose guidance |
| US11617522B2 (en) | 2019-08-06 | 2023-04-04 | Medtronic Minimed, Inc. | Sensor inserter with disposal lockout state |
| US11883208B2 (en) | 2019-08-06 | 2024-01-30 | Medtronic Minimed, Inc. | Machine learning-based system for estimating glucose values based on blood glucose measurements and contextual activity data |
| US11724045B2 (en) | 2019-08-21 | 2023-08-15 | Medtronic Minimed, Inc. | Connection of a stopper and piston in a fluid delivery device |
| US11571515B2 (en) | 2019-08-29 | 2023-02-07 | Medtronic Minimed, Inc. | Controlling medical device operation and features based on detected patient sleeping status |
| US11565044B2 (en) | 2019-09-12 | 2023-01-31 | Medtronic Minimed, Inc. | Manufacturing controls for sensor calibration using fabrication measurements |
| US11654235B2 (en) | 2019-09-12 | 2023-05-23 | Medtronic Minimed, Inc. | Sensor calibration using fabrication measurements |
| US11801344B2 (en) | 2019-09-13 | 2023-10-31 | Insulet Corporation | Blood glucose rate of change modulation of meal and correction insulin bolus quantity |
| US11213623B2 (en) | 2019-09-20 | 2022-01-04 | Medtronic Minimed, Inc. | Infusion systems and related personalized bolusing methods |
| US11241537B2 (en) | 2019-09-20 | 2022-02-08 | Medtronic Minimed, Inc. | Contextual personalized closed-loop adjustment methods and systems |
| US11935637B2 (en) | 2019-09-27 | 2024-03-19 | Insulet Corporation | Onboarding and total daily insulin adaptivity |
| US11511099B2 (en) | 2019-10-08 | 2022-11-29 | Medtronic Minimed, Inc. | Apparatus for detecting mating of a cap with a fluid delivery device and method |
| US11638545B2 (en) | 2019-10-16 | 2023-05-02 | Medtronic Minimed, Inc. | Reducing sensor foreign body response via high surface area metal structures |
| US11496083B2 (en) | 2019-11-15 | 2022-11-08 | Medtronic Minimed, Inc. | Devices and methods for controlling electromechanical actuators |
| US11944784B2 (en) | 2019-11-18 | 2024-04-02 | Medtronic Minimed, Inc. | Combined analyte sensor and infusion set |
| US11324881B2 (en) | 2019-11-21 | 2022-05-10 | Medtronic Minimed, Inc. | Systems for wearable infusion port and associated pump |
| US11559624B2 (en) | 2019-11-21 | 2023-01-24 | Medtronic Minimed, Inc. | Systems for wearable infusion port and associated pump |
| US11278671B2 (en) | 2019-12-04 | 2022-03-22 | Icu Medical, Inc. | Infusion pump with safety sequence keypad |
| US20210174960A1 (en) | 2019-12-09 | 2021-06-10 | Medtronic Minimed, Inc. | Generative modeling methods and systems for simulating sensor measurements |
| US20210183522A1 (en) | 2019-12-13 | 2021-06-17 | Medtronic Minimed, Inc. | Method and system for training a mathematical model of a user based on data received from a discrete insulin therapy system |
| US11488700B2 (en) | 2019-12-13 | 2022-11-01 | Medtronic Minimed, Inc. | Medical device configuration procedure guidance responsive to detected gestures |
| US11786655B2 (en) | 2019-12-13 | 2023-10-17 | Medtronic Minimed, Inc. | Context-sensitive predictive operation of a medication delivery system in response to gesture-indicated activity changes |
| US11938301B2 (en) | 2019-12-13 | 2024-03-26 | Medtronic Minimed, Inc. | Controlling medication delivery system operation and features based on automatically detected muscular movements |
| WO2021119593A1 (en) * | 2019-12-13 | 2021-06-17 | The Brigham And Women's Hospital, Inc. | Control of a therapeutic delivery system |
| US11375955B2 (en) | 2019-12-18 | 2022-07-05 | Medtronic Minimed, Inc. | Systems for skin patch gravity resistance |
| US11690573B2 (en) | 2019-12-18 | 2023-07-04 | Medtronic Minimed, Inc. | Systems for skin patch gravity resistance |
| US11833329B2 (en) | 2019-12-20 | 2023-12-05 | Insulet Corporation | Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns |
| US11821022B2 (en) | 2019-12-23 | 2023-11-21 | Medtronic Minimed, Inc. | Ethylene oxide absorption layer for analyte sensing and method |
| CN111261256A (en) * | 2020-01-19 | 2020-06-09 | 湖南盈赛缇思人工智能公共数据平台有限公司 | Insulin administration method, storage medium and system based on big data |
| US11244753B2 (en) | 2020-01-30 | 2022-02-08 | Medtronic Minimed, Inc. | Activity monitoring systems and methods |
| US11551802B2 (en) | 2020-02-11 | 2023-01-10 | Insulet Corporation | Early meal detection and calorie intake detection |
| US11547800B2 (en) | 2020-02-12 | 2023-01-10 | Insulet Corporation | User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system |
| US11324889B2 (en) | 2020-02-14 | 2022-05-10 | Insulet Corporation | Compensation for missing readings from a glucose monitor in an automated insulin delivery system |
| US11833327B2 (en) | 2020-03-06 | 2023-12-05 | Medtronic Minimed, Inc. | Analyte sensor configuration and calibration based on data collected from a previously used analyte sensor |
| USD958167S1 (en) | 2020-03-23 | 2022-07-19 | Companion Medical, Inc. | Display screen with graphical user interface |
| USD958817S1 (en) | 2020-03-31 | 2022-07-26 | Medtronic Minimed, Inc. | Display screen with graphical user interface |
| US11607493B2 (en) | 2020-04-06 | 2023-03-21 | Insulet Corporation | Initial total daily insulin setting for user onboarding |
| US11596359B2 (en) | 2020-04-09 | 2023-03-07 | Medtronic Minimed, Inc. | Methods and systems for mitigating sensor error propagation |
| US11690955B2 (en) | 2020-04-23 | 2023-07-04 | Medtronic Minimed, Inc. | Continuous analyte sensor quality measures and related therapy actions for an automated therapy delivery system |
| US11583631B2 (en) | 2020-04-23 | 2023-02-21 | Medtronic Minimed, Inc. | Intuitive user interface features and related functionality for a therapy delivery system |
| US11272884B2 (en) | 2020-06-04 | 2022-03-15 | Medtronic Minimed, Inc. | Liner for adhesive skin patch |
| CA3189781A1 (en) | 2020-07-21 | 2022-01-27 | Icu Medical, Inc. | Fluid transfer devices and methods of use |
| US11650248B2 (en) | 2020-07-28 | 2023-05-16 | Medtronic Minimed, Inc. | Electrical current measurement system |
| US11684716B2 (en) | 2020-07-31 | 2023-06-27 | Insulet Corporation | Techniques to reduce risk of occlusions in drug delivery systems |
| US11445807B2 (en) | 2020-07-31 | 2022-09-20 | Medtronic Minimed, Inc. | Pump clip with tube clamp for a fluid infusion device |
| US11839743B2 (en) | 2020-10-07 | 2023-12-12 | Medtronic Minimed, Inc. | Graphic user interface for automated infusate delivery |
| US11737783B2 (en) | 2020-10-16 | 2023-08-29 | Medtronic Minimed, Inc. | Disposable medical device introduction system |
| US11806503B2 (en) | 2020-10-29 | 2023-11-07 | Medtronic Minimed, Inc. | Removable wearable device and related attachment methods |
| US11844930B2 (en) | 2020-10-29 | 2023-12-19 | Medtronic Minimed, Inc. | User-mountable electronic device with accelerometer-based activation feature |
| US11534086B2 (en) | 2020-10-30 | 2022-12-27 | Medtronic Minimed, Inc. | Low-profile wearable medical device |
| US11951281B2 (en) | 2020-11-11 | 2024-04-09 | Medtronic Minimed, Inc. | Fluid conduit insertion devices |
| US11135360B1 (en) | 2020-12-07 | 2021-10-05 | Icu Medical, Inc. | Concurrent infusion with common line auto flush |
| US11904140B2 (en) | 2021-03-10 | 2024-02-20 | Insulet Corporation | Adaptable asymmetric medicament cost component in a control system for medicament delivery |
| US11904146B2 (en) | 2021-06-08 | 2024-02-20 | Medtronic Minimed, Inc. | Medicine injection devices, systems, and methods for medicine administration and tracking |
| US11792714B2 (en) | 2021-06-16 | 2023-10-17 | Medtronic Minimed, Inc. | Medicine administration in dynamic networks |
| US11850344B2 (en) | 2021-08-11 | 2023-12-26 | Mozarc Medical Us Llc | Gas bubble sensor |
| US11587742B1 (en) | 2021-09-02 | 2023-02-21 | Medtronic Minimed, Inc. | Ingress-tolerant input devices |
| US11817285B2 (en) | 2021-09-02 | 2023-11-14 | Medtronic Minimed, Inc. | Ingress-tolerant input devices comprising sliders |
| WO2023049900A1 (en) | 2021-09-27 | 2023-03-30 | Insulet Corporation | Techniques enabling adaptation of parameters in aid systems by user input |
| US11944733B2 (en) | 2021-11-18 | 2024-04-02 | Mozarc Medical Us Llc | Sodium and bicarbonate control |
| US11439754B1 (en) | 2021-12-01 | 2022-09-13 | Insulet Corporation | Optimizing embedded formulations for drug delivery |
| US11896447B2 (en) | 2022-03-14 | 2024-02-13 | Medtronic Minimed, Inc. | Safeguards against separation from portable medicine delivery devices |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2758467C2 (en) | 1977-12-28 | 1985-04-04 | Siemens AG, 1000 Berlin und 8000 München | Device for the pre-programmable infusion of liquids |
| US5364346A (en) * | 1985-12-20 | 1994-11-15 | Schrezenmeir Juergen | Process for the continuous and discontinuous administration of insulin to the human body |
| US4731726A (en) | 1986-05-19 | 1988-03-15 | Healthware Corporation | Patient-operated glucose monitor and diabetes management system |
| US4777953A (en) | 1987-02-25 | 1988-10-18 | Ash Medical Systems, Inc. | Capillary filtration and collection method for long-term monitoring of blood constituents |
| EP0290683A3 (en) | 1987-05-01 | 1988-12-14 | Diva Medical Systems B.V. | Diabetes management system and apparatus |
| US5216597A (en) | 1987-05-01 | 1993-06-01 | Diva Medical Systems Bv | Diabetes therapy management system, apparatus and method |
| NL8702370A (en) | 1987-10-05 | 1989-05-01 | Groningen Science Park | METHOD AND SYSTEM FOR GLUCOSE DETERMINATION AND USEABLE MEASURING CELL ASSEMBLY. |
| US5362307A (en) | 1989-01-24 | 1994-11-08 | The Regents Of The University Of California | Method for the iontophoretic non-invasive-determination of the in vivo concentration level of an inorganic or organic substance |
| GB2218831A (en) | 1988-05-17 | 1989-11-22 | Mark John Newland | Personal medical apparatus |
| US5222496A (en) | 1990-02-02 | 1993-06-29 | Angiomedics Ii, Inc. | Infrared glucose sensor |
| IL98203A (en) | 1990-06-20 | 1996-06-18 | Bayer Ag | Portable electronic logbook and method of storing and displaying data |
| US5251126A (en) | 1990-10-29 | 1993-10-05 | Miles Inc. | Diabetes data analysis and interpretation method |
| DE4221848C2 (en) | 1992-07-03 | 2001-04-12 | Eckhard Salzsieder | Method and arrangement for automatic in situ calibration of intracorporeal glucose measuring devices |
| US5425764A (en) | 1992-07-30 | 1995-06-20 | The University Of Toledo | Bioartificial pancreas |
| US5956501A (en) | 1997-01-10 | 1999-09-21 | Health Hero Network, Inc. | Disease simulation system and method |
| US5459317A (en) | 1994-02-14 | 1995-10-17 | Ohio University | Method and apparatus for non-invasive detection of physiological chemicals, particularly glucose |
| DE4415896A1 (en) | 1994-05-05 | 1995-11-09 | Boehringer Mannheim Gmbh | Analysis system for monitoring the concentration of an analyte in the blood of a patient |
| US5695949A (en) | 1995-04-07 | 1997-12-09 | Lxn Corp. | Combined assay for current glucose level and intermediate or long-term glycemic control |
| US5665065A (en) * | 1995-05-26 | 1997-09-09 | Minimed Inc. | Medication infusion device with blood glucose data input |
| FI118509B (en) | 1996-02-12 | 2007-12-14 | Nokia Oyj | A method and apparatus for predicting blood glucose levels in a patient |
| US5989917A (en) | 1996-02-13 | 1999-11-23 | Selfcare, Inc. | Glucose monitor and test strip containers for use in same |
| WO1997030778A1 (en) | 1996-02-23 | 1997-08-28 | Circle Biomedical, Inc. | Novel artificial pancreas |
| JP2000515778A (en) | 1996-07-08 | 2000-11-28 | アニマス コーポレーシヨン | Implantable sensors and systems for in vivo measurement and control of body fluid component levels |
| DE19632371A1 (en) | 1996-08-10 | 1998-05-20 | Eckhard Dipl Phys D Salzsieder | Method and arrangement for determining individual-specific insulin activity-equivalent physical activity |
| FI112545B (en) | 1997-05-30 | 2003-12-15 | Nokia Corp | Method and system for predicting the level of a glycosylated hemoglobin component in a patient's blood |
| US6558351B1 (en) | 1999-06-03 | 2003-05-06 | Medtronic Minimed, Inc. | Closed loop system for controlling insulin infusion |
| DE19725676A1 (en) | 1997-06-18 | 1998-12-24 | Walter Lauermann | Electronic storage method for medical especially nutritional data |
| US5997475A (en) | 1997-08-18 | 1999-12-07 | Solefound, Inc. | Device for diabetes management |
| US6269314B1 (en) | 1997-08-19 | 2001-07-31 | Omron Corporation | Blood sugar measuring device |
| US6024699A (en) | 1998-03-13 | 2000-02-15 | Healthware Corporation | Systems, methods and computer program products for monitoring, diagnosing and treating medical conditions of remotely located patients |
| DE19814219A1 (en) * | 1998-03-31 | 1999-10-07 | Roche Diagnostics Gmbh | Insulin medication control procedures |
| EP1159030B1 (en) | 1999-03-05 | 2007-06-13 | Impulse Dynamics N.V. | Blood glucose level control |
| US6925393B1 (en) | 1999-11-18 | 2005-08-02 | Roche Diagnostics Gmbh | System for the extrapolation of glucose concentration |
| DE10006044A1 (en) | 2000-02-10 | 2001-08-16 | Roche Diagnostics Gmbh | System, useful for administering hormone for blood glucose regulation of patient, comprises regulation unit with controller for processing measured data, and device for administering hormone |
-
2001
- 2001-07-31 US US09/918,623 patent/US6544212B2/en not_active Expired - Lifetime
-
2002
- 2002-07-24 CA CA002394900A patent/CA2394900C/en not_active Expired - Lifetime
- 2002-07-27 DE DE60229693T patent/DE60229693D1/en not_active Expired - Lifetime
- 2002-07-27 ES ES02017012T patent/ES2316506T3/en not_active Expired - Lifetime
- 2002-07-27 AT AT02017012T patent/ATE413654T1/en not_active IP Right Cessation
- 2002-07-27 EP EP02017012A patent/EP1281351B8/en not_active Expired - Lifetime
- 2002-07-30 JP JP2002222013A patent/JP4231253B2/en not_active Expired - Lifetime
-
2005
- 2005-12-14 JP JP2005360620A patent/JP2006175227A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2316506T3 (en) | 2009-04-16 |
| EP1281351B1 (en) | 2008-11-05 |
| EP1281351A3 (en) | 2004-03-24 |
| US20030028089A1 (en) | 2003-02-06 |
| ATE413654T1 (en) | 2008-11-15 |
| DE60229693D1 (en) | 2008-12-18 |
| JP2003079723A (en) | 2003-03-18 |
| JP4231253B2 (en) | 2009-02-25 |
| EP1281351B8 (en) | 2009-03-04 |
| EP1281351A2 (en) | 2003-02-05 |
| CA2394900A1 (en) | 2003-01-31 |
| JP2006175227A (en) | 2006-07-06 |
| US6544212B2 (en) | 2003-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2394900C (en) | Diabetes management system | |
| US11147921B2 (en) | Adjusting insulin delivery rates | |
| US20210193285A1 (en) | A system and method for use in disease treatment management | |
| US20170332952A1 (en) | Insulin delivery system and methods with risk based set points | |
| EP2260462B1 (en) | System for optimizing a patient's insulin dosage regimen | |
| JP2022541491A (en) | blood sugar control system | |
| CA2753210C (en) | Cgm-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery | |
| US8945085B2 (en) | Method and device for calculating a bolus amount | |
| US20110098548A1 (en) | Methods for modeling insulin therapy requirements | |
| US20100298685A1 (en) | Adaptive insulin delivery system | |
| US20200015760A1 (en) | Method to determine individualized insulin sensitivity and optimal insulin dose by linear regression, and related systems | |
| Pinsker et al. | Evaluation of an artificial pancreas with enhanced model predictive control and a glucose prediction trust index with unannounced exercise | |
| CN108289642B (en) | Medical arrangement and method for determining insulin therapy related parameters, predicting glucose values and providing insulin delivery recommendations | |
| US20240131259A1 (en) | Adjusting insulin delivery rates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20220725 |